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1. INTRODUCTION 
 Oral route of drug administration is most appealing route for delivery of 
drugs of various dosage forms. The tablets is one of the most preferred dosage form 
because of its ease of administration, accurate dosing and stability as compared to 
oral liquid dosage forms and when compared to capsules, tablets are more temper 
evident. 
1.1 TABLETS1: 
 Tablets may be defined as solid unit pharmaceutical dosage forms 
containing drug substance with or without suitable Excipients and prepared by either 
compression or molding mehtods1. The first step in the development of dosage form 
is Preformulation, which can be defined as investigation of physicochemical 
properties of drug substance alone and when combined with Excipients. The main 
objective of Preformulation studies, is to develop stable and bioavilabel dosage form 
and study of factors affecting such stability, bioavailability and to optimize so as to 
formulate the best dosage form, here optimization of formulation means finding the 
best possible composition2.  compressed tablets are formed by applying pressure, for 
which compression machines (tablet presses) are used and they are made from 
powdered crystalline or granular material, alone or in combination with binder, 
disintegrants, release polymers, lubricants and diluents and in some cases colorant. 
1.1.1 Various types of tablets2 
A)  Oral tablets for ingestion 
 These tablets are meant to be swallowed intact along with a sufficient 
quantity of potable water. Exception is chewable tablet. Over 90% of the tablets 
manufactured today are ingested orally. This shows that this class of formulation is 
the most popular worldwide and the major attention of the researcher is towards this 
direction. 
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 1. Standard compressed tablets 
 2 Multiple compressed tablets 
  a. Compression coated tablet 
  b. Layered tablet 
  c. Inlay tablet 
 3. Modified Release tablet 
 4.  Delayed action tablet 
 5.  Targeted tablet 
  a. Floating tablet 
  b. Colon targeting tablet 
 6. Chewable tablet 
 7. Dispersible tablet 
B)  Tablets used in the oral cavity 
 The tablets under this group are aimed release active pharmaceutical 
ingredient in oral cavity or to provide local action in this region. The tablets under 
this category avoids first-pass metabolism, decomposition in gastric environment, 
nauseatic sensations and gives rapid onset of action. The tablets formulated for this 
region are designed to fit in proper region of oral cavity. 
 1. Lozenges and troches 
 2. Sublingual tablet 
 3. Buccal tablet 
 4. Dental cones 
 5. Mouth dissolved tablet 
 
 
 Introduction 
 
Department of Pharmaceutics, 
Annai veilankanni’s pharmacy college. 
3 
C  Tablets administered by other routes 
 These tablets are administered by other route except for the oral cavity and 
so the drugs are avoided from passing through gastro intestinal tract. These tablets 
may be inserted into other body cavities or directly placed below the skin to be 
absorbed into systemic circulation from the site of application. 
 1. Vaginal tablet 
 2. Implants 
D  Tablets used to prepare solution 
 The tablets under this category are required to be dissolved first in water or 
other solvents before administration or application. This solution may be for ingestion 
or parentral application or for topical use depending upon type of medicament used. 
 1. Effervescent tablet 
 2. Hypodermic tablet 
1.2 FORMULATION OF TABLETS: 
 In addition to active pharmaceutical agent (API), the tablets contain non 
drug substances called as Excipients, which include: 
Table-1.1 Excipients in Tablet Formulation and their Functions2,3 
Diluents or Fillers         Diluents make the required bulk of the tablet when the drug 
dosage itself is inadequate to produce tablets of adequate 
weight and size. 
Binders/ Granulating     
agents                              
Provides cohesiveness to powders, thus providing the 
necessary bonding to form granules. 
Disintegrates                   Facilitate a breakup or disintegration of the tablet when placed 
in an aqueous environment. 
Antifrictional Agents 
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Lubricants         Reduce the friction during tablet formation in a die and also 
during ejection from die cavity. 
Anti adherents                 Reduce sticking or adhesion of any of the tablet granulation or 
powder to the faces of the punches or to the die wall. 
Glidants                          Promote the flow of tablet granulation or powder mixture from 
hopper to the die cavity by reducing friction between the 
particles. 
Miscellaneous 
Wetting agents               Aid water uptake during disintegration and assist drug 
dissolution. 
Dissolution 
retardants     
Retards the dissolution of active pharmaceutical ingredients. 
Dissolution 
enhancers     
Enhance the dissolution rate of active pharmaceutical 
ingredients. 
Adsorbents                     Retain large quantities of liquids without becoming wet; this 
property allows many oils, fluid extracts to be incorporated into 
tablets. 
Buffers                           Provide suitable micro environmental pH to get improved 
stability and / or bioavailability. 
Antioxidants                   Prevents oxidation and maintains the product stability. 
Chelating agents             Protect against autoxidation; they act by forming complexes 
with the heavy metal ions which are often required to initiate 
oxidative reactions. 
Preservatives                   Prevent the growth of micro-organisms. 
Colors & flavors          Provides attractiveness, increase patient compliance and 
product identification.  
  
Sweeteners                      Sweeteners are added to mask bitter taste of tablets 
  
 
 
 
 Introduction 
 
Department of Pharmaceutics, 
Annai veilankanni’s pharmacy college. 
5 
1.3 Tablet: Manufacturing Methods2, 3, 4 
1.3.1 Wet granulation 
 The most widely used process of agglomeration in pharmaceutical industry 
is wet granulation. Wet granulation process simply involves wet massing of the 
powder blend with a granulating liquid, wet sizing, drying and compression. 
Raw materials → Weighing → Screening → wet mass → Sieving/Milling → drying 
→ screening → Mixing → Compression 
1.3.2 Dry granulation 
 In dry granulation process the powder mixture is compressed without the 
use of heat and solvent. Two methods are used for dry granulation. The more widely 
used method is slugging, where the powder is pre compressed and the resulting tablet 
or slug are milled to yield the granules and the compressed to tablets. 
 Raw material → Weighing → Screen → Mixing → Slugging →Milling → 
Screening → Mixing → Compression                                                              
1.3.3 Direct compression 
 Direct compression is a more efficient and economical process as 
compared to other processes, because it involves only dry blending and compaction 
of API and necessary excipients. 
Raw material →Weighing → screening → Mixing → Compression 
1.3.4 Defects in tablet manufacturing 2, 3 
 Lamination: Separation of a tablet into two or more distinct 
horizontal layers. 
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 Capping: Partial or complete separation of top or bottom crowns of 
a tablet. 
 Chipping: Breaking of tablet edges during compression or coating. 
 Cracking: Fine cracks observed on the upper and lower central 
surface of tablets, or very rarely on the sidewall are referred to as 
‘Cracks’. 
 Picking: In picking the tablet material adheres to the surface of the 
punches resulting in tablets with a pitted surface instead of a smooth 
surface. 
 Sticking: The tablet material adhers to the die wall. 
 Mottling: Unequal distribution of colour on the surface of coloured 
tablets. 
 Blotting: Appearance of light or dark spots of colour on the tablet 
surface. 
 Double Impression: It involves only those punches, which have a 
monogram or other engraving on them. Free travel or free rotation of 
either upper punch or lower punch during ejection of a tablet causes 
double impression.                         
1.4 ORAL DISINTEGRATING TABLETS 
 The most important drug delivery route is undoubtedly the oral route. It 
offers advantages of convenience of administration and potential manufacturing cost 
savings. Drugs that are administered orally, solid oral dosage forms in general and 
tablets in particular represent the preferred class of product. Today drug delivery 
companies are focusing on solid oral drug delivery systems that offer greater patient 
compliance and effective dosages. Tablet is the most popular among all dosage forms 
existing today because of its convenience of self administration, compactness and 
easy manufacturing. Many patients find it difficult to swallow tablets and hard gelatin 
capsules and do not take their medication as prescribed. In a survey conducted by 
Honda and Nakano, half of the patients experienced difficulty taking medication, 
such as tablet and capsule which results in a high incidence of non-compliance and 
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ineffective therapy. The difficulty is experienced in particular by paediatric and 
geriatric patients, but it also applies to people who are ill in bed and to those active 
working patients who are busy or traveling, especially those who have no access to 
water.5 Over a decade, the demand for development of orally disintegrating tablets 
(ODTs) has enormously increased as it has significant impact on the patient 
compliance. Orally disintegrating tablets offer an advantage for populations who have 
difficulty in swallowing. It has been reported that Dysphagia (difficulty in 
swallowing) is common among all age groups and more specific with pediatric, 
geriatric population along with institutionalized patients and patients with nausea, 
vomiting, and motion sickness complications. ODTs with good taste and flavor 
increase the acceptability of bitter drugs by various groups of population. Orally 
disintegrating tablets are also called as orodispersible tablets, quick disintegrating 
tablets, mouth dissolving tablets, fast disintegrating tablets, fast dissolving tablets, 
rapid dissolving tablets, porous tablets, and rapimelts. However, of all the above 
terms, United States pharmacopoeia (USP) approved these dosage forms as ODTs. 
Recently, European Pharmacopoeia has used the term orodispersible tablet for tablets 
that disperses readily and within 3 min in mouth before swallowing. United States 
Food and Drug Administration (FDA) defined ODT as “A solid dosage form 
containing medicinal substance or active ingredient which disintegrates rapidly 
usually within a matter of seconds when placed upon the tongue.” The disintegration 
time for ODTs generally ranges from several seconds to about a minute. 6 
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1.41  Historical perspective of ODT 
 Products of ODT technologies entered the market in the 1980’s, have 
grown steadily in demand, and their product pipelines are rapidly expanding. The first 
ODT form of a drug to get approval from the US (FDA) was a Zydis ODT of Claritin 
(Loratadine) in December 1996. It was followed by a ZYDIS ODT formulation of 
Klonopin (Clonazepam) in December 1997, and a ZYDIS ODT formulation of 
Maxalt (Rizatriptan) in June 1998. CATALENT PHARMA SOLUTIONS in the 
U.K., CIMA LABS in the U.S. and TAKEDA Pharmaceutical Company in Japan lead 
in the development of ODTs7.  
 
 
 
 
 
Figure-1.1 Consumer Preferences for ODT’s8 
 Recent market studies indicate that most of the patient population prefers 
ODTs to other dosage forms and would ask their doctors for ODTs (70%), purchase 
ODTs (70%), or prefer ODTs to regular tablets or liquids (>80%). In addition, several 
business needs are driving ODT technology development and the commercialization 
of new products such as the need for expanded product lines, improved life-cycle 
management, extended patent life, and marketing advantages7,8. 
1.42 Drug Selection Criteria 
 The ideal characteristics of a drug for oral dispersible tablet include 9 
 Ability to permeate the oral mucosa. 
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 At least partially non-ionized at the oral cavity pH. 
 Have the ability to diffuse and partition into the epithelium of the 
upper GIT. 
 Small to moderate molecular weight. 
 Low dose drugs preferably less than 50 mg. 
 Short half life and frequent dosing drugs are unsuitable for ODT. 
 Drug should have good stability in saliva and water. 
 Very bitter or unacceptable taste and odour drugs are unsuitable for 
ODT. 
1.43 Important Criteria for Excipients used in the Formulation of ODTS: 
 It must be able to disintegrate quickly. 
 Their individual properties should not affect the ODTs. 
 It should not have any interactions with drug and other excipients. 
 It should not interfere in the efficacy and organoleptic properties of 
the product. 
 When selecting binder a (single or combination of binders) care must 
be taken in the final integrity and stability of the product. 
 The melting points of excipients used will be in the range of 30-
350C. 
 The binders may be in liquid, semi liquid, solid or polymeric 
mixtures10. 
 (Ex: Polyethylene glycol, cocoa butter, hydrogenated vegetable oils) 
1.44 Advantages 11, 12 
 Easy to administer to the patient who cannot swallow such as 
pediatric, geriatric, bedridden, stroke victim and institutionalized 
patient ( specially for mentally retarded and psychiatric patients) 
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 Pregastric absorption leading to increased bioavaibility rapid 
absorption of drugs from mouth, pharynx and oesophagus as saliva 
passes down to stomach, also avoids hepatic metabolism. 
 Convenient for administration to travelling patients and busy people 
who do not have accesses to water. 
 Excellent mouths feel property produced by use of flavours and 
sweetners help to change the perception of “medication as bitter pill” 
especially in pediatric population. 
 Fast disintegration of tablets leads to quick dissolution and rapid 
absorption which may produce rapid onset of action. 
 ODTs offer all the advantages of solid dosage forms and liquid 
dosage forms. 
 Convenience of administration and accurate dosing compared to 
liquids. 
1.45 Challenges in the Formulation of Orally Disintegrating Tablets 
Palatability13, 14 
 As most drugs are unpalatable, orally disintegrating drug delivery systems 
usually contain the medicament in a taste-masked form. Delivery systems disintegrate 
or dissolve in patient’s oral cavity, thus releasing the active ingredients which come 
in contact with the taste buds; hence, taste-masking of the drugs becomes critical to 
patient compliance 
Mechanical strength15, 16, 17 
 In order to allow ODTs to disintegrate in the oral cavity, they are made of 
either very porous and soft-molded matrices or compressed into tablets with very low 
compression force, which makes the tablets friable and/or brittle, difficult to handle, 
and often requiring specialized peel-off blister packing that may add to the cost. Only 
few technologies can produce tablets that are sufficiently hard and durable to allow 
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them to be packaged in multidose bottles, such as Wowtab® by Yamanouchi-
Shaklee, and Durasolv® by CIMA labs. 
Hygroscopicity18 
 Several orally disintegrating dosage forms are hygroscopic and cannot 
maintain physical integrity under normal conditions of temperature and humidity. 
Hence, they need protection from humidity which calls for specialized product 
packaging 
Amount of drug13, 19 
 The application of technologies used for ODTs is limited by the amount of 
drug that can be incorporated into each unit dose. For lyophilized dosage forms, the 
drug dose must be lower than 400 mg for insoluble drugs and less than 60 mg for 
soluble drugs. This parameter is particularly challenging when formulating a fast-
dissolving oral films or wafers. 
Aqueous solubility20, 21 
 Water-soluble drugs pose various formulation challenges because they 
form eutectic mixtures, which result in freezing-point depression and the formation of 
a glassy solid that may collapse upon drying because of loss of supporting structure 
during the sublimation process. Such collapse sometimes can be prevented by using 
various matrix-forming excipients such as Mannitol than can induce crystallinity and 
hence, impart rigidity to the amorphous composite. 
Size of tablet22 
 The degree of ease when taking a tablet depends on its size. It has been 
reported that the easiest size of tablet to swallow is 7-8 mm while the easiest size to 
handle was one larger than 8 mm. Therefore, the tablet size that is both easy to take 
and easy to handle is difficult to achieve. 
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Table-1.2 Drugs Explored for Orally Disintegrating Tablets.23 
Category Drug 
NSAIDS 
Ketoprofen, Piroxicam, Paracetomol, Rofecoxib, Nimesulide, 
Ibuprofen 
Anti ulcer Famotidine, Lansoprazole 
Anti 
parkinsonism 
Selegiline 
Anti depressants Mitraxepine, Fluoxetine, Escitalopram Oxalate 
Anti migrane Sumatriptan, Rizatriptan benzoate, Zolmitriptan 
Anti histaminics Loratadine, Diphenhydramine, Meclizine 
Hypnotics 
sedatives 
Zolpidem, Clonazepam, Atenolol 
Anti psychotics Olanzepine, Pirenzepine, Risperidone 
Anti emetics Ramosetoron HCl, Ondansetron 
Miscellaneous 
Ethenzamide, Baclofen, Hydrochlorthiazide, Tramodol Hcl, 
Propyphenazone,   Spiranolactone,   Phloroglucinol, Sildenafil 
 
1.5 Various Approaches Employed in Manufacture of ODTS 
 There are number of techniques generally employed in the formulation of 
orally disintegrating dosage forms. These techniques have their own advantages as 
well as disadvantages and are described below: 
1.51 Direct compression 
 Direct compression is one of the popular techniques for preparation of 
these dosage forms. The advantages of this method include easy implementation, use 
of conventional equipments along with commonly available excipients, limited 
number of processing steps and cost effectiveness. Disintegration and solubilization 
of directly compressed tablets depend on single or combined action of disintegrants, 
water-soluble excipients and effervescent agents. The basic principle involved in 
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development of these dosage forms using this technique is addition of 
Superdisintegrants in optimum concentrations so as to achieve rapid disintegration 
along with pleasant mouth feel 24. It is considered as the best method to prepare orally 
disintegrating dosage forms since the prepared tablets offer higher disintegration due 
to absence of binder and low moisture contents 25. This approach is also considered as 
disintegrant addition technology.  
1.52 Freeze drying 
 Freeze drying or lyophilization is a process in which solvent is removed 
from a frozen drug solution or suspension containing structure forming excipients. 
Tablets formulated by this technique are usually very light and porous in nature 
which allows their rapid dissolution. Glassy amorphous porous structure of excipients 
as well as the drug substance produced with freeze drying results in enhanced 
dissolution. Freeze drying process normally consists of three steps: 
 Material is frozen to bring it below the eutectic point. 
 Primary drying to reduce the moisture around 4% w/w of dry 
product. 
 Secondary drying to reduce the bound moisture upto required final 
volume. 
 Entire freeze drying process is carried out at non elevated temperature; 
therefore, nullifying adverse thermal effects that may affect drug stability during 
processing24. R.P. Scherer patented zydis technology utilizing lyophilization or freeze 
drying process in development of mouth dissolving tablets on the basis of patents 
issued to Gregory et al 26,27. Corveleyn Sam et al also prepared rapidly disintegrating 
tablets by lyophilization 28 
1.53 Sublimation 
 Because of low porosity, compressed tablets containing highly water-
soluble excipients as tablet matrix material often do not dissolve rapidly in water. 
Some inert volatile substances like urea, urethane, ammonium carbonate, 
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naphthalene, camphor etc. are added to other tablet excipients and blend is 
compressed into tablet. Removal of volatile substances by sublimation generates a 
porous structure. Various steps involved in sublimation process are shown in Figure 
1. Additionally several solvents like cyclohexane and benzene etc. can also be used as 
pore forming agents. 
                                            
 
 
 
 
 
Figure 1.2: Steps involved in sublimation process 
 Koizumi et al formulated rapidly saliva soluble tablets using camphor as 
subliming agent. The tablets were subjected to vacuum at 80ºC for 30 min. to 
eliminate camphor and thus create pores in the tablet. Porous tablet exhibits good 
mechanical strength and dissolve quickly29. Gohel M. et al prepared mouth dissolving 
tablets of nimesulide using vacuum drying technique and found that it would be an 
effective alternative approach compared to the use of more expensive adjuvants in the 
formulation of these dosage forms 30 
1.54 Moulding 
 Moulded tablets are designed to facilitate the absorption of active 
ingredients through mucosal linings of mouth. This is achieved by complete and rapid 
dissolution of the tablet using water soluble ingredients. Moulded tablets disintegrate 
more rapidly and offer improved taste because of the dispersion matrix which is 
 Introduction 
 
Department of Pharmaceutics, 
Annai veilankanni’s pharmacy college. 
15 
generally prepared from water soluble sugars. Powdered blend (containing drug and 
excipients like binding agents - sucrose, acacia, PVP etc.) is pushed through a very 
fine screen (to ensure rapid dissolution) and then moistened with a hydroalcoholic 
solvent and moulded into tablets under pressure lower than employed for 
conventional compressed tablets. The solvent is later removed by air drying. A porous 
structure that enhances dissolution prepared by using water soluble ingredients meant 
to be absorbed through mucosal lining of mouth, thus increasing bioavailability and 
decreasing first pass metabolism of certain drugs.  
1.55 Spray drying 
 This technique is based upon the use of a particulate support matrix 
prepared by spray drying an aqueous composition containing support matrix and 
other components to form a highly porous and fine powder. Allen et al utilized this 
process for preparing ODTs. These formulations consisted of 
hydrolyzed/unhydrolyzed gelatin as supporting agent for matrix, mannitol as bulking 
agent, and sodium starch glycolate or croscarmellose sodium as disintegrating agent. 
Disintegration and dissolution were further improved by adding effervescent 
components, i.e. citric acid and sodium bicarbonate. The formulation was finally 
spray dried to yield a porous powder 31. 
1.56 Mass extrusion 
 This technology consist of softening the active blend using a solvent 
mixture of water soluble Polyethylene glycol with methanol and expulsion of 
softened mass through the extruder or syringe to obtain cylinder of the product into 
even segments employing heated blade to form tablet. The dried cylinder can also be 
utilized for coating the granules of bitter drugs and thereby masking their taste31,32  
1.57 Cotton candy process 
 This process is so named as it utilizes an inimitable spinning mechanism to 
produce floss like crystalline structure, which mimics cotton candy. This technique 
involves formation of matrix of polysaccharides or saccharides by simultaneous 
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action of flash melting and spinning. The matrix formed is partially recrystallized to 
have better flow properties and compressibility. This matrixis milled and blended 
with active ingredients as well as excipients and subsequently compressed to ODTs. 
This process can accommodate high doses of drug and offers improved mechanical 
strength. However, high process temperature limits the use of this process31. 
1.58 Phase transition 
 Kuno etal proposed a novel method to prepare ODTs with sufficient 
hardness by involving the phase transition of sugar alcohol. In this technique, ODTs 
are produced by compressing and subsequently heating tablets that contain two sugar 
alcohols, one with high and other with a low melting point. Heating process enhances 
the bonding among particles leading to sufficient ardness of tablets which was 
otherwise lacking owing to low/little compactibility 33. 
1.59 Melt granulation 
 Melt granulation is a process in which pharmaceutical powders are 
efficiently agglomerated by the use of binder which can be a molten liquid, a solid or 
a solid that melts during the process. For accomplishing this process, high shear 
mixers are utilized, where the product temperature is raised above the melting point 
of binder by a heating jacket or by the heat of friction generated by impeller blades. 
Perissutti et al prepared carbamazepine fast-release tablets by melt granulation 
technique using polyethylene glycol 4000 as a melting binder and lactose 
monohydrate as hydrophilic filler 34, 35. 
1.6 Important Patented Technologies for Fast Dissolving Tablets36-40 
Zydis Technology 
 Zydis formulation is a unique freeze dried tablet in which drug is 
physically entrapped or dissolved within the matrix of fast dissolving carrier material. 
When zydis units are put into the mouth, the freeze-dried structure disintegrates 
instantaneously and does not require water to aid swallowing. The zydis matrix is 
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composed of many material designed to achieve a number of objectives. To impart 
strength and resilience during handling, polymers such as gelatin, dextran or alginates 
are incorporated. These form a glossy amorphous structure, which imparts strength. 
To obtain crystallinity, elegance and hardness, saccharides such as mannitol or 
sorbitol are incorporated. Water is used in the manufacturing process to ensure 
production of porous units to achieve rapid disintegration while various gums are 
used to prevent sedimentation of dispersed drug particles in the manufacturing 
process. 
Durasolv Technology:  
 Durasolv is the patented technology of CIMA labs. The tablets made by 
this technology consist of drug, filler and a lubricant. Tablets are prepared by using 
conventional tabletting equipment and have good rigidity. These can be packaged into 
conventional packaging system like blisters. Durasolv is an appropriate technology 
for product requiring low amounts of active ingredients. 
Orasolv Technology:  
 CIMA labs have developed Orasolv Technology. In this system active 
medicament is taste masked. It also contains effervescent disintegrating agent. Tablets 
are made by direct compression technique at low compression force in order to 
minimize oral dissolution time. Conventional blenders and tablet machine is used to 
produce the tablets. The tablets produced are soft and friable. 
Flash Dose Technology: 
 Flash dose technology has been patented by fuisz. Nurofen meltlet, a new 
form of ibuprofen as melt in mouth tablets prepared using flash dose technology is the 
first commercial product launched by Biovail Corporation. Flash dose tablets consist 
of self-binding shear form matrix termed as “floss”. Shear form matrices are prepared 
by flash heat processing. 
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Wow tab Technology 
 Wow tab technology is patented by Yamanouchi Pharmaceutical Co.WOW 
means “Without Water”. In this process, combination of low mouldability saccharides 
and high mouldability saccharides is used to obtain a rapidly melting strong tablet. 
The active ingredient is mixed with a low mouldability saccharide (eg. lactose, 
glucose, and mannitol) and granulated with a high mouldability saccharide (eg. 
Maltose, oligosaccharides) and compressed into tablet. 
Flash tab Technology:  
 Prographarm laboratories have patented the Flash tab technology. Tablet 
prepared by this system consists of an active ingredient in the form of micro crystals. 
Drug micro granules may be prepared by using the conventional techniques like  
oacervation, micro encapsulation and extrusion spheronisation. All the processing 
utilized conventional tabletting technology. 
OraQuick:  
 The OraQuick fast-dissolving/disintegrating tablet formulation utilizes a 
patente taste masking technology. KV Pharmaceutical claims its microsphere 
technology,known as MicroMask, has superior mouthfeel over taste-masking 
alternatives. The taste masking process does not utilize solvents of any kind, and 
therefore leads to faster and more efficient production. 
Quick –Dis Technology: 
 Lavipharm Laboratories Inc. (Lavipharm) hass invented an ideal intraoral 
fast-dissolving drug delivery system, which satisfies the unmet needs of the market. 
The novel intraoral drug delivery system, trademarked Quick- Dis™, is Lavipharm’s 
proprietary patented technology and is a thin, flexible, and quick-dissolving film. The 
film is placed on the top or the floor of the tongue. It is retained at the site of 
application and rapidly releases the active agent for local and/or systemic absorption. 
The Quick-Dis™ drug delivery system can be provided in various packaging 
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configurations, ranging from unitdose pouches to multiple-dose blister packages. The 
typical disintegration time, which is defined as the time at which the film begins to 
break when brought into contact with water, is only 5 to 10 seconds for the Quick- 
Dis™ film with a thickness of 2 mm. drug delivery system is 50% released within 30 
seconds and 95% within 1 minute. 
Durasolv Technology 
 DuraSolv is Cima’s second-generation fast-dissolving/disintegrating tablet 
formulation. Produced in a fashion similar to OraSolv, DuraSolv has much higher 
mechanical strength than its predecessor due to the use of higher compaction 
pressures during tableting. DuraSolv tablets are prepared by using conventional 
tabletting equipment and have good rigidity (friability less than that 2%). The 
DuraSolv product is thus produced in a faster and more costeffective manner. 
DuraSolv is so durable that it can be packaged in traditional blister packaging, 
pouches or vials. One disadvantage of DuraSolv is that the technology is not 
compatible with larger doses of active ingredients, because the formulation is 
subjected to such high pressures on compaction. Unlike OraSolv, the structural 
integrity of any taste masking may be compromised with high drug doses. The drug 
powder coating in DuraSolv may become fractured during compaction, exposing the 
bitter-tasting drug to a patient’s taste buds. Therefore, the DuraSolv technology is 
best suited for formulations including relatively small doses of active compound. 
Sheaform Technology 
 This technology make Sheaform matrix consisting of floss preparation. 
Floss is produced by subjecting to a feedshock containing a sugar to flash heat 
processing. 
Ceform Technology 
 In this technology microspheres containing active ingredient are 
prepared.Basic requirement of this technology is placing dry powder containing either 
pure drug or special blend of drug and excipients. The microspheres then mixed and 
compressed into previously selected oral dosage form.  
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Lyoc (Laboratories L. Lafon, Maisons Alfort, France) 
 Lyoc utilizes a freeze drying process but differ from Zydis in that the 
product is frozen on the freeze dryer shelves. To prevent inhomogeneity by 
sedimentation during this process, these formulations require a large proportion of 
undissolved inert filler (mannitol), to increase the viscosity of the inprocess 
suspension. The high proportion of filler reduces the potential porosity of the dried 
dosage form and results in denser tablets with disintegration rates that are 
Comparable with the loosely compressed fast melt formulations. 
Pharmaburst technology 
 Pharmaburst™ is a “Quick Dissolve” delivery system patented by SPI 
Pharma. Pharmaburst is a co-processed excipient system with specific excipients, 
which allows rapid disintegration and low adhesion to punch facesmouldablilty 
saccharides are used to obtain rapid melting strong tablet. The active ingredient mixes 
with low mouldablilty saccharides. 
Frosta technology 
 Akina patents this technology. It utilizes the concept of formulating plastic 
granules and compressing them at low pressure to produce strong tablets with high 
porosity. Plastic granules composed of porous and plastic material, water penetration 
enhancer, and binder. The process involves mixing the porous plastic material with 
water penetration enhancer followed by granulating with binder. The tablets obtained 
have excellent hardness and rapid disintegration time ranging from 15 to 30 sec 
depending on size of tablet. 
Nano technology 
 For fast dissolving tablets, Elan’s proprietary NanoCrystal technology can 
enable formulation and improve compound activity and final product characteristics. 
Decreasing particle size increases the surface area, which leads to an increase in 
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dissolution rate. This can be accomplished predictably and efficiently using 
NanoCrystal technology. NanoCrystal™ Fast dissolving technology provides for: 
 Pharmacokinetic benefits of orally administered nanoparticles (<2 
microns) in the form of a rapidly disintegrating tablet matrix 
 Product differentiation based upon a combination of proprietary and 
patent-protected technology elements. 
 Cost-effective manufacturing processes that utilize conventional, 
scalable unit operations. 
Table-1.3 ODT Patented Technologies and Corresponding Commercial Products 41 
Technologies Company 
name 
Products on market 
DuraSolv®, 
OraSolv® CIMA 
Tempra®, Quicklet/Tempra®, FirsTabs, Trimainic ®, 
Softchews (several formulations), Remeron®, 
SolTabs, Zomig® Rapimelt, Nulev®, Alavert®, 
FazaClo, Parcopa, Niravam, Clarinex Redi Tabs 
Flash Dose  Biovail Neruofen 
Flashtab  Ethypharm Nurofen 
Kryotab  Biotron None 
OraQuick  KV Pharmaceutical None 
Quick-Dis  Lavipharm Lab Film none 
RapitrolTM  Shire Lab None 
Slow-DisTM  Lavipharm Lab Film none 
WOWTAB  Yamanouchi Benadryl Fastmelt 
Advatab  Eurand None 
Zydis  Cardinal Health Maxalt MLT, Claritin Reditabs, Zyprexa Zydis, Zofran ODT 
Lyoc  Cephalon Proxalyoc (piroxicam), Paralyoc (paracetamol), SpasponLyoc (loperamide) 
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1.7 Possible Benefits of Orally Disintegrating Drugs42, 43. 
Clinical 
 Improved drug absorption 
 Faster onset of action 
 Minimized first-pass effect 
 Improved bioavailability 
Medical  
 No tablet or capsule to swallow or chew. 
 Better taste, no water needed. 
 Improved safety and efficacy. 
 Improved compliance 
 The risk of chocking or suffocation during oral administration of 
conventional formulations due to physical obstruction is avoided, 
thus providing improved safety. 
Technical 
 More accurate dosing than liquid products. 
 Can use sugars and other excipients that are generally recognized as 
safe. 
 Improved stability because of unit-dose packaging. 
 Manufacturing with common process and conventional equipment. 
Business 
 Unique product differentiation 
 Value-added product line extension 
 Marketing exclusivity 
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 Extended patent protection  
 Product differentiation 
 Line extension and life cycle management. 
 Exclusivity of product promotion 
1.8 Super Disintegrants and ODT44 
 Superdisintegrant plays the major role in oral disintegrating tablet. The 
disintegration efficiency is based on the force-equivalent concept (the combined 
measurement of swelling force development and amount of water absorption). 
Superdisintegrants are generally used at a low level in the solid dosage form, typically 
1 – 10 % by weight relative to the total weight of the dosage unit. 
  Common disintegrants used are Croscarmellose sodium (Vivasol, Ac-Di-
Sol), Crospovidone (Polyplasdone), Carmellose (NS-300), Carmellose calcium 
(ECG-505), Sodium starch glycolate (SSG) etc. Recently few ion exchange resins 
(e.g. Indion 414) are found to have superdisintegrant property and are widely used in 
pharmaceutical industry. 
1.8.1 Method of Addition of Disintegrants 
 Disintegrants are essentially added to tablet granulation for causing the 
compressed tablet to break or disintegrate when placed in aqueous environment. 
There are three methods of incorporating disintegrating agents into the tablet:  
I. Internal Addition (Intragranular) 
II. External Addition (Extragranular)  
III. Partly Internal and External  
 In external addition method, the disintegrant is added to the sized 
granulation with mixing prior to compression. In Internal addition method, the 
disintegrant is mixed with other powders before wetting the powder mixtures with the 
granulating fluid. Thus the disintegrant is incorporated within the granules. When 
these methods are used, part of disintegrant can be added internally and part 
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externally. This provides immediate disruption of the tablet into previously 
compressed granules while the disintegrating agent within the granules produces 
further erosion of the granules to the original powder particles.  
1.8.2 Mechanism of Tablet Disintegrants44 
 The tablets are broken into small pieces and then produces a homogeneous 
suspension which is based on the following mechanisms:  
Capillary action/ Water wicking 
 Disintegration by capillary action is always the first step. When we put the 
tablet into suitable aqueous medium, the medium penetrates into the tablet and 
replaces the air adsorbed on the particles, which weakens the intermolecular bond and 
breaks the tablet into fine particles. Water uptake by tablet depends upon 
hydrophilicity of the drug/excipient and on tableting conditions. The ability of a 
disintegrant to draw water into the porous network of a tablet is essential for effective 
disintegration. Wicking is not necessarily accompanied by a volume increase. 
By Swelling 
 Perhaps the most widely accepted general mechanism of action for tablet 
disintegration is swelling. It is worthwhile to note that if the packing fraction is very 
high, fluid is unable to penetrate into the tablet and disintegration again slows down. 
Air expansion /Heat of wetting  
When disintegrants with exothermic properties gets wetted, localized stress is 
generated due to capillary air expansion, which helps in disintegration of tablet.  
Due to disintegrating particle/particle repulsive forces 
 Another mechanism of disintegration attempts to explain the swelling of 
tablet made with ‘non-swellable’ disintegrants. Non-swelling particles cause 
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disintegration of tablets. The electric repulsive forces between particles are the 
mechanism of disintegration and water is required for it. Researchers found that 
repulsion is secondary to wicking. 
Due to deformation 
 During tablet compression, disintegrated particles get deformed and these 
deformed particles get into their normal structure when they come in contact with 
aqueous media or water. This increase in size of the deformed particles produces a 
breakup of the tablet. This may be a mechanism of starch and has only recently begun 
to be studied. 
Due to release of gases 
 Carbon dioxide is released within tablets on wetting due to interaction 
between bicarbonate and carbonate with citric acid or tartaric acid. The tablet 
disintegrates due to generation of pressure within the tablet. The effervescent blend is 
either added immediately prior to compression or can be added in to two separate 
fraction of formulation. 
By Enzymatic reaction 
 Here, enzymes presents in the body act as disintegrants. These enzymes 
destroy the binding action of binder and helps in disintegration.     
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Mechanism of Action of Superdisintegrant 
 
 
 
 
Figure1.3:  Mechanism of action of Superdisintegrant 
                      Table-1.4 Superdisintegrants employed in ODTs.45,46. 
Superdisintegrant Nature Properties Mechanism 
Crosspovidone 
 
Crosslinked homo 
polymer of N-
vinyl-2-
pyrrolidone 
Particle size - 100ìm. 
Insoluble in water. 
Gives smoother mouth 
feel. 
Both swelling 
and wicking 
Cross carmellose 
sodium 
Cross-linked form 
of sodium CMC 
Particle size - 200ìm. 
Insoluble in water. Swelling 
Sodium starch 
glycolate 
Crosslinked low 
substituted 
carboxy methyl 
ether of poly-
glucopyranose 
Particle size - 140mesh. 
Insoluble in organic 
solvents, disperses in 
cold water and settles 
in the form of a highly 
saturated layer.  
Water uptake 
followed by 
rapid and 
enormous 
swelling. 
Acrylic acid 
derivatives 
Poly (acrylic acid) 
super porous 
hydrogel 
Particle size - 106ìm. 
DT – 15 + 2 s Wicking action 
Effervescent mixture 
Citric acid, 
tartaric acid, 
sodium 
bicarbonate.  
Crystalline nature Effervescence 
Sodium alginate Sodium salt of 
alginic acid 
Slowly soluble in 
water, hygroscopic in 
nature 
Swelling 
L-HPC Low hydroxy propyl cellulose 
Particle size - 106ìm. 
DT – 90 s 
Both swelling 
and wicking 
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Table-1.5 ODT Products Available in International Market.47 
Brand name Active ingredient Company 
Alavert   Loratadine Wyeth Consumer Healthcare 
Cibalginadue FAST  Ibuprofen   Novartis Consumer Health 
Hyoscyamine Sulfate ODT   Hyoscyamine sulfate   ETHEX Corporation 
NuLev   Hyoscyamine sulfate   Schwarz Pharma 
Fluoxetine ODT     Fluoxetine Bioavail 
Benadryl Fastmelt Diphenhydramine Pfizer 
Nurofen flash tab Ibuprofen Boots Healthcare 
Zomig ZMT & Rapimelt   Zolmitriptan   Astra Zeneca 
Fluoxetine ODT  Fluoxetine   Bioavail 
Excedrin Quick Tabs   Acetaminophen   Bristol-Myers Squibb 
Claritin RediTabs  Loratadine   Sching Corporation 
Remeron SolTab     Mirtazepine Organon Inc 
Feldene Melt   Piroxicam   Pfizer 
Propulsid Quicksolv Cisapride 
monohydrate   Janssen 
Imodium Instant melts   Loperamide HCL   Janssen 
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2. REVIEW OF LITERATURE 
 
 Syama sundar.b et al, 48 carried out a simple, specific, accurate and 
precise RP-HPLC method was developed and validated for the determination of 
escitalopram oxalate in tablet dosage forms. A hypersil BDS C8, 5- column having 
250x4.6mm internal diameter in isocratic mode with mobile phase containing 
methanol: disodium hydrogen phosphate: acetonitrile (28:44:28v/v, pH 7.0±0.05) 
was used. The flow rate was 1.5ml/min and effluents were monitored at 226nm. The 
retention time of escitalopram oxalate was 8.45 min. The linearity range is 250-
1500-g/ml with coefficient of correlation 0.9999. The method was validated in terms 
of accuracy, precision, repeatability. The percentage recovery for escitalopram 
oxalate was found to be 99.0%. The proposed method was successfully applied for 
quantitative determination of escitalopram oxalate in single dosage form for routine 
analysis. 
 Chaudhari et al, 49 developed simple, rapid, accurate and precise assay 
procedure based on Spectrophotometric method has been developed for the 
estimation of Escitalopram oxalate (ESC) in Pharmaceutical formulation. The 
method was based on the bromination of ESC with a known excess amount of 
bromate-bromide mixture in acid medium followed by the determination of surplus 
bromine by reacting with dye methyl orange and measuring the absorbance at 507 
nm. The proposed method was linear over the range of 2-14 μg/mL with the 
correlation co-efficient (r) of 0.9983 and the mean recovery for ESC was 100.5 %. 
The intermediate precision data obtained under different experimental setup, the 
calculated value of co-efficient of variance (CV, %) was found to be 1.14 % for both 
day to day and within a day variation. The proposed method can be successfully 
applied for the analysis of tablet formulations. 
 Sanjay Sharma et al, 50 developed a method to estimate Escitalopram 
oxalate and Clonazepam in combination are available as tablet dosage forms in the 
ratio of 20:1. A simple, precise, accurate, reproducible and efficientmethod for the 
simultaneous determination of Escitalopram oxalate and Clonazepam tablet dosage 
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form was developed. The proposed method is based on thesimultaneous estimation 
by UV Spectroscopy, using multi-component mode of analysis. 80% (v/v) aqueous 
methanol was used as blank (reference solvent). Thedeveloped method was 
validated and successfully applied to estimation of Escitalopram oxalate and 
Clonazepam in combination in tablet formulations. 
 Tapobana samanta et al, 5 1study indicates a simple, accurate and precise 
RP‐HPLC method for the estimation of Escitalopram in bulk and in pharmaceutical 
formulations. The mobile phase used was phosphate buffer with pH 7.0 and an 
organic mixture solvent (acetonitrile and methanol in the ratio of 1:1 v/v). Then the 
mobile phase was prepared by mixing buffer solution and mixture of organic 
solvents in the ratio of (55: 45 v/v) respectively. The specification of the 
chromatographic system 150 mm ×4.6 mm Xterra RP 18, 5 μm, flow rate 
1.2ml/min, detection 238nm, injection volume 10μl and run time 10 min. Only very 
few HPLC procedures have been reported in the literature for the determination of 
Escitalopram in pharmaceutical formulations and biological fluids. There are no 
reports for the determination of Escitalopram by HPLC in pure form. Hence I have 
made an attempt to develop a HPLC method for the determination of Escitalopram 
in bulk and in pharmaceutical formulations. 
 Kanij Fatema et al, 52Nefopam and Escitalopram are INN drugs and as 
such it has not been yet included in the BP or USP. The objective of this work is to 
develop a simple, sensitive, accurate, precise and reproducible UVS 
pectrophotometric method for quantitative estimation of Nefopam and Escitalopram 
in tablet dosage forms. Various solvents were used to find out the medium for 
maximum solubility of each drug. The _max of Nefopam and Escitalopram was 
266nm and 284nm in water respectively. Both drugs obey Beer- Lambert’s law in 
the range of 50-400μg/ml for Nefopam and 25-200μg/ml for Escitalopram. The 
correlation coefficients of std. curves were 0.998 and 0.995. The values of SD were 
0.131 and 0.081 respectively. %RSD (Relative standard deviation) of interday 
absorbance of Nefopam was 0.766 and Escitalopram was 0.854. The LOD (Limit of 
Detection) were 0.393 and 0.243 and LOQ (Limit of Quantification) were 1.310 and 
0.810 respectively. The percent potencies were 92.16 and 102.06 for Nefopam and 
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Escitalopram. The potency of these tablets complied with their claimed quantity 
(±10%). 
 Sharma. S et al, 53developed a new, simple, fast and reliable zero order 
spectrophotometric method has been developed for determination of Escitalopram 
Oxalate in bulk and tablet dosage forms. The quantitative determination of drug was 
carried out using the zero order values (absorbance) measured at 238 nm. 
Calibration graph constructed at 238 nm was linear in concentration range of 2-20 
µg/ml with correlation coefficient 0.9999. The method was found to be precise, 
accurate, specific, and validated as per ICH guidelines and can be used for 
determination of Escitalopram Oxalate in tablet formulations. 
 Kakde R. B. et al, 54 carried out a accurate and precise spectrophotometric 
method has been developed for simultaneous estimation of escitalopram oxalate and 
clonazepam in combined dosage form. Simultaneous equation method is employed 
for simultaneous determination of escitalopram oxalate and clonazepam from 
combined dosage forms. In this method, the absorbance was measured at 238 nm for 
escitalopram oxalate and 273 nm for clonazepam. Linearity was observed in range 
of 5-100 μg/ml and 5-50 μg/ml for escitalopram and clonazepam respectively. 
Recovery studies confirmed the accuracy of proposed method and results were 
validated as per ICH guidelines. The method can be used for routine quality control 
of pharmaceutical formulation containing escitalopram and clonazepam. 
 Kalpesh gur et al, 55developed the fast disintegrating tablets of 
aceclofenac were prepared by subliming method with a view to enhance patient 
compliance. In this paper, two super-disintegrants, viz., crospovidone and sodium 
starch glycolate were used in different ratio (2-8 % w/w) with camphor (30 % w/w) 
as subliming agent. The prepared batches of tablets were evaluated for thickness, 
weigh variation, hardness, friability, drug content uniformity, wetting time, water 
absorption ratio, in-vitro disintegration time and in-vitro drug release. Based on 
disintegration time (approximately 21 second), three formulations were tested for the 
in-vitro drug release pattern (in ph 7.4 phosphate buffer). Among the three 
promising formulations, the formulation prepared by using 8% w/w of crospovidone 
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and emerged as the overall best formulation based on the in-vitro drug release 
characteristics.  
 Uma vasi reddy et al, 56compared the effect of superdisintegrants on the 
mouth dissolving property of salbutamol sulphate tablets. Orodispersible tablets of 
salbutamol sulphate of prepared using sodium starch glycollate, crosscarmellose 
sodium as superdisintegrants. The results revealed that the tablets containing 
subliming agent had a good dissolution profile. The optimized formulation showed 
good release profile with maximum drug being released at all time intervals. This 
work helped us in understanding the effect of formulation processing variables 
especially the super disintegrants on the drug release profile. The present study 
demonstrated potentials for rapid absorption improved bioavailability effective 
therapy and patient compliance. 
 Prameela rani. A et al, 57 metformin hcl (met.hcl) is an orally 
administered hypoglycemic agent, used in the management of non‐insulin‐dependent 
(type‐2 )diabetes. As precision of dosing and patient’s compliance become important 
prerequisite for a long term antidiabetic treatment, there is a need to develop 
formulation for this drug which overcomes problems such as difficulty in 
swallowing, inconvenience in administration while travelling and patient’s 
acceptability. Hence in the present study an attempt has  een made to prepare fast 
disintegrating tablets of met.hcl in the oral cavity with enhanced dissolution rate. 
The tablets were prepared with isphagula husk, natural superdisintegrant and 
crosspovidone, synthetic superdisintegrant. The pure drug and formulation blend 
was examined for angle of repose, bulk density, tapped density, commpressibility 
index and haussner’s ratio. The tablets were evaluated for hardness, tensile strength, 
drug content, friability and were found satisfactory. The disintegration time in the 
oral cavity was also tested and was found to be around 10sec. Based on dissolution 
rate the disintegrants can be rated as isphagula husk > crosspovidone. Hence 
ishagula husk was recommended as suitable disintegrant for the preparation of direct 
compression melt‐in‐mouth tablets of met.hcl. All the dissolution parameters were 
calculated and compared with market tablet. A 3.78 fold increase in the dissolution 
rate was observed with f4 formulation when compared to market tablet(glucophage). 
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It was concluded that the rapidly disintegrating tablets with proper hardness, rapid 
disintegration in the oral cavity with enhanced dissolution rate can be made using 
super disintegrants. 
 Basani g et al, 58 baclofen is a muscle relaxant and anti spastic. The 
present investigation deals with the formulation of oral disintegrating tablets of 
baclofen that disintegrate in the oral cavity upon contact with saliva and there by 
improve therapeutic efficacy. The odts were prepared by direct compression 
technique. The optimized formulation was also prepared by effervescent method. 
The influence of superdisintegrants, Crospovidone, croscaremellose sodium and 
sodium starch glycolate at three levels on disintegration time, wetting time and water 
absorption ration were studied. Tablets were evaluated for weight and thickness 
variation, disintegration time, drug content, in vitro dissolution, wetting time and 
water absorption ratio. The in vitro disintegration time of the best odts was found to 
be 14 sec and 28sec by direct compression and by effervescent method, respectively. 
Tablets containing crospovidone exhibit quick disintegration time than tablets 
containing croscaremellose sodium, sodium starch glycolate and effervescent 
mixture. Good correlation was observed between water absorption ratio and dt. The 
directly compressible rapidly disintegrating tablets of baclofen with shorter 
disintegration time, acceptable taste and sufficient hardness could be prepared using 
crospovidone and other excipients at optimum concentration. 
 Jyotsana madan et al, 59the objective of this work was to prepare and 
evaluate fast dissolving tablets of the nutraceutical, freeze dried aloe vera gel.fast 
dissolving tablets of the nutraceutical, freeze-dried aloe vera gel, were prepared by 
dry granulation method. The tablets were evaluated for crushing strength, 
disintegration time, wetting time, friability, drug content and drug release. A 32 full 
factorial design was applied to investigate the combined effect of two formulation 
variables - amounts of microcrystalline cellulose and mannitol. The results of 
multiple regression analysis revealed that in order to obtain a fast dissolving tablet of 
the aloe vera gel, an optimum concentration of mannitol and a higher content of 
microcrystalline cellulose should be used. A response surface plot was also provided 
to graphically represent the effect of the independent variables on the disintegration 
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time and wetting time. The validity of the generated mathematical model was tested 
by preparing a check point batch.conclusion: this investigation has demonstrated that 
satisfactory fast dissolving aloe vera gel tablets can be formulated. It also showed 
the potential of experimental design in understanding the effect of formulation 
variables on the quality of fast dissolving tablets. 
 Jashanjit singh et al, 60purpose: the objective of this study was to 
formulate and optimize an orodispersible formulation of meloxicam using a 2 
factorial design for enhanced bioavailability.the tablets were made by non-aqueous 
wet granulation using crospovidone and mannitol. A 2 factorial design was used to 
investigate the amount of crospovidone and taste masking, soothening hydrophilic 
agent (mannitol), as independent variables, and disintegration time as dependent 
response. Formulated orodispersible tablets were evaluated for weight variation, 
friability, disintegration time, drug content, wetting time, water absorption ratio and 
in vitro drug release. The results show that the presence of a superdisintegrant and 
mannitol is desirable for orodispersion. All the formulations satisfied the limits of 
orodispersion with a dispersion time of less than 60 sec. For example, formulation f4 
showed a disintegration time of 32.1 sec, crushing strength of 4.93 kg/cm2, drug 
content of 98.5% and fast drug release rate of 99.5% within 30 min, as compared 
with the conventional tablet (49.5%) . It is feasible to formulate orodispersible 
tablets of meloxican with acceptable disintegration time, rapid drug release and good 
hardness, which could be amenable to replication on an industrial scale. 
 furtado et al, 61 purpose of the present research was to the effect of 
camphor as a subliming agent on the mouth dissolving property of famotidine 
tablets. Method: orodispersible tablets of famotidine were prepared using camphor 
as subliming agent and sodium starch glycollate together with crosscarmellose 
sodium as superdisintegrants. The formulations were evaluated for weight variation, 
hardness, friability, drug content, wetting time, in vitro and in-vivo dispersion, 
mouth feel and in vitro dissolution. Result: all the formulations showed low weight 
variation with dispersion time less than 30 seconds and rapid in vitro dissolution. 
The results revealed that the tablets containing subliming agent had a good 
dissolution profile. The drug content of all the formulations was within the 
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acceptable limits of the united states pharmacopoeia xxvii. The optimized 
formulation showed good release profile with maximum drug being released at all 
time intervals. Conclusion: this work helped in understanding the effect of 
formulation processing variables especially the subliming agent on the drug release 
profile. The present study demonstrated potentials for rapid absorption, improved 
bioavailability, effective therapy and patient compliance. 
 Anand et al,62 prepare taste-masked orally disintegrating tablets (odts) of 
prednisolone (pdl) by incorporation of microspheres in the tablets for use in specifi c 
populations viz. Pediatrics, geriatrics and patients experiencing diffi culty in 
swallowing. Methods: microsphere containing pdl were prepared by the solvent 
evaporation method using acetone as solvent for ph-sensitive polymer and light 
liquid paraffi n as the encapsulating medium. Prepared microspheres were 
characterized with regard to the yield, drug content, particle size and size 
distribution, surface features, in vitro drug release and taste. Tablets, prepared by 
direct compression containing microspheres, were evaluated with regard to crushing 
strength, friability, disintegration time, drug content and in vitro drug release and 
taste. Results: the results obtained showed that the average size of microspheres is 
infl uenced greatly by the speed of stirring. Microspheres prepared by the solvent 
evaporation method in acetone were of a regular spherical shape with satisfactory 
results in terms of the size and size distribution. The comparison of the dissolution 
profi les of microspheres in different media shows that microspheres produce a 
retarding effect in ph 6.8 buffer. Taste evaluation studies confi rmed that 
microspheres of pdl having a drug to polymer ratio of 1: 10 are tasteless and these 
were further used for formulation into odts. Compression of microspheres resulted in 
breaking of a fraction of the microspheres but this did not  dversely affect the taste. 
Conclusion: effective taste-masking was achieved for pdl using the technique of  
icroencapsulation and odts of acceptable characteristics were obtained by 
disintegrant addition and direct compression. 
 Venkata ramana reddy S et al,63 develop oral disintegrating tablets (odt) 
of low bitter hypertensive drugs like amlodipine besylate using tastem enhancers as 
a taste  asking agents. Odt of amlodipine besylate were prepared using different 
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superdisintegrants by direct compression method. Mannitol was used as a diluent 
and sodium lauryl sulphate was used as a wetting (surfactant) agent. Aspartame and 
acesulfame potassium were used for unpleasant taste masked from the amlodipine 
besylate by cosifting and serial of blending with other excipients. The mixed final 
blend was then compressed into tablets. The formulations were evaluated for weight 
variation, hardness, friability, wetting time, disintegrating time, dissolution, taste 
valuation study and in vitro dissolution. All the formulation showed low weight 
variation with different disintegration time and rapid in vitro dissolution. The results 
revealed that the tablets containing taste enhancers had a good palatability for the 
patients. The optimized formulation showed good taste masking, less disintegration 
time (<30seconds) and release profile with maximum drug being released at all time 
intervals. The present study demonstrated potentials for rapid disintegration in oral 
cavity without water, improved taste masking and patient compliance. 
 Anantha lakshmi pallikonda et al, 64 formulate and evaluate 
domperidone mdt’s. It acts as an ant emetic used in the treatment of motion sickness. 
Different batches of tablets were prepared using higher and lower concentrations of 
superdisintegrants like croscarmellose sodium, crospovidone (c.p), sodium starch 
glycolate (ssg), while mcc was used as diluents. Tablets were prepared by slugging 
method. Different evaluations tests like hardness, friability, wetting and 
disintegration times, % drug release were performed. Tablets containing along with 
crospovidone were disintegrate rapidly below 20sec and % drug release is 99% at 
4th minute. Tablets with added patient benefits and increased consumer satisfaction. 
 Mahaveer pr. Khinchi et al, 65 super disintegrants (such as ac-di-sol, 
crospovidone, sodium starch glycolate), diluents (dibasic calcium phosphate) along 
with sweetening agent (aspartame) were used in the formulation of tablets. The 
tablets were evaluated for hardness, friability, water absorption ratio, in-vitro 
disintegration time (dt), in-vitro disintegration time in oral cavity and in vitro drug 
release. Using the same excipients, the tablets were prepared by direct compression 
and were evaluated in the similar way. Maximum drug release and minimum dt were 
observed with crospovidone excipient prepared by direct compression. 
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 Dr. Raghavendra rao n. et al, 66 carried out the study on novel co-
processed super disintegrants were developed by solvent evaporation method using 
crospovidone and sodium starch glycolate in different ratios (1:1, 1:2 and 1:3) for 
use in the fast dissolving tablet formulations. The developed excipients were 
evaluated for angle of repose, carr’s index and hausner’s ratio in comparison with 
physical mixture of superdisintegrants. Fast dissolving tablets of felodipine were 
prepared using the above co-processed superdisintegrants and evaluated for pre-
compression and postcompression parameters. Effect of co-processed 
superdisintegrants (such as crospovidone, and sodium starch glycolate) on wetting 
time, disintegrating time, drug content, in-vitro release, and stability parameters 
have been studied. From this study, it can be concluded that dissolution rate of 
felodipine could be enhanced by tablets containing co-processed superdisintegrant. 
 Suhas m. Kakade et al, 67 Orally disintegrating tablets prepared by direct 
compression and using super disintegrants like crospovidone, croscarmellose 
sodium and sodium starch glycolate designate, designated as three different groups 
of formulation ( a, b and c) respectively were prepared and evaluated for the 
precompression parameters such as bulk density, compressibility, angle of repose 
etc. The prepared batches of tablets were evaluated for hardness, weight variation, 
friability, drug content, disintegration time and in-vitro dissolution profile and found 
satisfactory. Among the three groups, group (c) containing crospovidone emerged as 
the best formulation and showed maximum dissolution rate with 98.49% drug 
release in 15 min. All three groups of formulations released the drug at faster rates 
than that of marketed conventional tablets of sertraline. 
 Deshpande kiran bhaskar et al, 68 carrriedout the  study was aimed, 
which can disintegrate or dissolve rapidly once placed in the oral cavity. Propranolol 
hydrochloride is a antihypertensive drug, which undergoes extensive hepatic 
degradation (96%), which have poor oral bioavailability (26%) for overcoming this 
problem orodispersible tablets of propranolol hydrochloride can be formulated 
which avoids extensive first pass metabolism and improvement in dissolution 
efficacy, disintegration time which results in improvement in bioavailability. The 
advantage of this formulation is such that in case of hypertension attack patient can 
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take the drug without the usage of water. Therefore the main objective of the present 
work is to develop orodispersible tablets of propranolol hydrochloride to improve 
bioavailability, disintegration time, dissolution efficacy and patient compliance. 
 Tejash serasiya et al, 69orodispersible tablets of pheniramine maleate 
were prepared by direct compression method using various superdisintegrants like 
crospovidone, croscarmellose sodium, sodium starch glycolate, low substituted 
hydroxypropyl cellulose, pregelatinized starch. The prepared tablets were evaluated 
for uniformity of weight, hardness, friability, wetting time, in-vitro disintegration 
time, in-vitro  dispersion time and drug release study. All the formulation exhibited 
hardness between 3.3 – 3.6 kg/cm2. The tablets were disintegrating in–vitro within 
20 to 51 sec. Dissolution studies revealed that formulations containing 10% 
crospovidone and formulation containing 10% croscarmellose sodium showed 100% 
of drug release, at the end of six min. The concentration of superdisintegrants had an 
effect on disintegration time and in-vitro drug dissolution whereas hardness and 
friability of resulting tablets were found to be independent of disintegrant 
concentration. The two formulations, one containing 10% of crospovidone and 
second containing 10% croscarmellose sodium were found to give the best results. 
 Pankaj p. Amrutkar et al,70. Carried out the work on  lamotrigine used in 
the treatment of depression and bipolar disorder. But it is a bitter drug and slightly 
soluble in water. Thus, in the work under taken, an attempt was made to mask the 
taste and to formulate into a chewable dispersible tablet by complexation with 
precirol ato-05, which also acts as taste masking agent. Since, these tablets can be 
swallowed in the form of dispersion; it is suitable dosage form for paediatric and 
geriatric patients. Drug-precirol ato-05 was prepared in drug to precirol ato-05 ratio 
of 1:2, 1:1.5, 1:1, 1:0.5. The prepared tablets were evaluated for general appearance, 
content uniformity, hardness, friability, taste evaluation, mouth feel, in vitro 
disintegration time, and in vitro dissolution studies. Tablets with precirol ato-05 
have shown good disintegrating features, also, the dispersion not showing any bitter 
taste, indicate the capability of precirol ato-05 used, both as taste masking agents. 
Almost more than 90 percent of drug was released from the formulation within 1 h. 
Further formulations were subjected to stability testing for 3 months at temperatures 
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25±5ºc/60±5%rh; 30±5ºc/65±5%rh and 40±5ºc/75±5%rh. Tablets have shown no 
appreciable changes with respect to taste, disintegration, and dissolution profiles. 
 Ganesh kumar gudas et al,71. Study an attempt has been made to prepare 
fast dissolving tablets of chlorpromazine hcl in the oral cavity with enhanced 
dissolution rate. The tablets were prepared with five superdisintegrants eg: sodium 
starch glycolate , crospovidone ,croscarmellose, l-hpc, pregelatinised starch , the 
blend was examined for angle of repose, bulk density, tapped density , 
compressibility index and hausners ratio. The tablets were evaluated for hardness, 
friability, disintegration time, dissolution rate, drug content, and were found to be 
within 1 min. It was concluded that the fast dissolving tablets with proper hardness, 
rapidly disintegrating with enhanced dissolution can be made using selected 
superdisintegrants. 
 Sradhanjali patra et al,72 metronidazole is an antiemetic and prokinetic 
drug used in the treatment of motion sickness in adults and children.as precision of 
dosing and patient’s compliance become important prerequisite for quick relief from 
motion sickness, there is a need to develop a formulation for this drug which 
overcomes problems such as difficulty in swallowing, inconvenience in 
administration while traveling and better compliance. Hence in the present research 
work mouth dissolving tablets of metronidazole were developed with 
superdisintegrants like crospovidone, indion 414, l – hpc and pregelatinised starch in 
various concentrations like 8 % and 10 % w/w by wet granulation method. All 
formulations were evaluated for physical characteristics of compressed tablets such 
as weight variation, hardness, friability, drug content, disintegration time and in vitro 
dissolution study. Among all, the formulation f4 (containing 10% w/w concentration 
of crospovidone) was considered to be the best formulation, having disintegration 
time of 27 sec, hardness 2.56 kg/cm2 and in vitro drug release of 92.23% in 15 min. 
All the formulation follows higuchi order release kinetics. 
 Prajapati et al, 73carriedout the work on  piroxicam which  has bad taste, 
half life of 30 hrs and poor water solubility. In the present work to develop taste 
masked orally disintegrating tablets of piroxicam, preformulation parameters like 
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solubility, particle size, tapped density, bulk density,hausner ratio, carr’s 
compressibility index, angle of repose, and differential scanning calorimetry study 
were performed. Out of twelve formulations (f-1 to f-12), f-11 formulation 
containing crospovidone xl 10 %, drug: polymer 1:0.35 , aspartame 6% and sodium 
lauryl sulphate 0.5%, showed optimum characteristics of orodispersible tablet (odt) 
of piroxicam with sufficient crushing strength (5.5 to 6.5 kp), friability (0.18%), 
wetting time (28 sec) and disintegration time (22 sec). In-vitro dissolution profile 
studies revealed that 82.3% drug was released within 5 min. The study concluded 
that crospovidone xl and eudragit epo can successfully be used as superdisintegrant 
and taste masking excipient respectively. 
 Pasupathi et.al,74.carried out the ork on lamotrigine chewable-dispersible 
tablet was prepared by using crosspovidone xl10, as a disintegrating agent, different 
grades of mannitol (pearlitol 160 c, pearlitol sd 200, pearlitol 500dc) as a diluents, 
pvp k30 as a binder and carried out studies for weight variation, thickness, hardness, 
content uniformity, disintegrating time, dispersion time, wetting time, in vitro drug 
release and stability study. Tablets were prepared by using direct compression 
method and wet granulation method. Furthermore, impact of different punches and 
superdisintegrants (sodium starch glycolate, and sodium crosscarmalose) were 
carried on f16 formulation. 
 Ashok Kumar et al, 75 investigation was to develop orally disintegrating 
tablets of terbutaline sulphate. Granules containing drug, diluent, subliming agents, 
aspartame were prepared by wet granulation technique using alcoholic solution of 
polyvinyl pyrrolidone K25 (10% w/v) as a binder. The dried granules were then 
mixed with lubricant magnesium stearate and glidant talc and compressed into 
tablets. Subliming agents was sublimed from the tablet by exposing it to drying at 65 
0C. The tablets were evaluated for percentage friability, hardness, weight variation, 
disintegration time and percentage drug content. Menthol containing tablets resulted 
in rapid disintegration as compared with tablets containing ammonium bicarbonate 
and camphor. Formulations F4 showed the minimum disintegration time of 16s. 
Formulations tested for all the official tests for tablets and were found to be within 
limits. 
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 Madhusudan rao Y et al, 76 deals with formulation of orodispersible 
tablets (ODT) of buspirone that disintegrate in the oral cavity upon contact with 
saliva and thereby should improve therapeutic efficacy. The ODTs were prepared by 
wet granulation and direct compression techniques. The optimized formulation was 
also prepared by freeze drying method. The influence of superdisintegrants, 
crospovidone, croscarmellose sodium and sodium starch glycolate at three levels on 
disintegration time, wetting time and water absorption ratio were studied. Tablets 
were evaluated for weight and thickness variation, disintegration time, drug content, 
in vitro dissolution, wetting time and water absorption ratio. 
 Pandey Shivanand et al,77development of taste masked orally 
disintegrating tablets are to increase patient compliance, ease of administration, 
safety and appropriate dosing. Orally disintegrating formulations also provide 
benefits for pharmaceutical companies like lifecycle management, line extension, 
market expansion, cost effective drug development programs. This technology has 
perceived faster onset of action (only if engineered for absorption in the oral cavity 
or stomach) as the dosage form is disintegrated prior to reaching the stomach and is 
ideal for acute diseases like hypertension and heart failure and particularly 
applicable to manage breakthrough symptoms. Fast dissolving tablets (FDT), tablet 
that disintegrates and dissolves rapidly in saliva without need of drinking water. The 
FDT usually dissolve in the oral cavity in about 10 seconds to 3 minutes. Faster the 
drug goes into solution, the quicker absorption and onset of clinical effect. 
 PK Bhoyar et al, 78 present work was to mask the taste of ondansetron 
hydrochloride and to formulate its patient-friendly dosage form. Complexation 
technique using indion 234 (polycyclic potassium with carboxylic functionality) and 
an ion-exchange resin was used to mask the bitter taste and then the taste-masked 
drug was formulated into an orodispersible tablet (ODT). The drug loading onto the 
ion-exchange resin was optimized for mixing time, activation, effect of pH, mode of 
mixing, ratio of drug to resin and temperature. The resinate was evaluated for taste 
masking and characterized by X-ray diffraction study and infrared spectroscopy. 
ODTs were formulated using the drug–resin complex. The developed tablets were 
evaluated for hardness, friability, drug content, weight variation, content uniformity, 
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friability, water absorption ratio, in vitro and in vivo disintegration time and in vitro 
drug release. The tablets disintegrated in vitro and in vivo within 24 and 27 s, 
respectively. Drug release from the tablet was completed within 2 min. The obtained 
results revealed that ondansetron HCl has been successfully taste masked and 
formulated into an ODT as a suitable alternative to the conventional tablets. 
 Shailesh Sharma et al, 79formulate promethazine theoclate fast-
dissolving tablets that offer a suitable approach to the treatment of nausea and 
vomiting The solubility of promethazine theoclate was increased by formulating it as 
a fast-dissolving tablet containing _-cyclodextrin, crospovidone, and camphor, using 
direct compression method. A 33 full factorial design was used to investigate the 
combined influence of three independent variables – amounts of camphor, 
crospovidone and _-cyclodextrin - on disintegration time, friability and drug release 
after 5 min. The optimization study, involving multiple regression analysis, revealed 
that optimum amounts of camphor, crospovidone and _-cyclodextrin gave a rapidly 
disintegrating/dissolving tablet. A Check point batch was also prepared to verify the 
validity of the evolved mathematical model. The optimized tablet should be 
prepared with an optimum amount of _-cyclodextrin (3.0 mg), camphor (3.2mg) and 
crospovidone (2.61 mg) which disintegrated in 30 s, with a friability of 0.60 % and 
drug release of 89 % in 5 min. 
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3. AIM AND OBJECTIVE 
 
AIM OF STUDY 
 To carry out preformulation study of excipients and their compatibility with 
the API. 
 Development of various formulations and preparation of ODT’s by direct 
compression technique. 
 Selection and optimization of the best formulation. 
 To conduct accelerated stability testing to the finished dosage form as per 
ICH guidelines 
OBJECTIVE OF STUDY 
 To carry out literature survey of drug molecules 
 To analyse the trial samples 
 To optimize the final formula 
 To conduct the stability studies of final formula 
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4. PLAN OF WORK 
 The present work was carried out to formulate Oral Disintegrating 
Escitalopram Oxalate tablets and to evaluate the invitro and stability studies for the 
prepared Escitalopram Oxalate tablets. It was planned to carry out this work as 
outlined below. 
 Characterization of drug substances and other excipients. 
 Formulation development of Escitalopram Oxalate Orally 
Disintegrating tablets by Direct Compression Technique.  
 Evaluation of the pre compressional parameters. 
 To evaluate the formulated Escitalopram Oxalate tablets for the 
following parameters. 
a) Tablet thickness. 
b) Weight variation. 
c) Tablet friability. 
d) Wetting time. 
e) Tablet hardness. 
f) Disintegration. 
g) In vitro dispersion time  
h) Dissolution 
i) Moisture absorption studies 
j) Assay  
 To carry out the stability studies for finalized formula of Orally 
Disintegrating Escitalopram Oxalate Tablet as per ICH guidelines. 
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5. DRUG PROFILE 81, 82, 83 
 
5.1 ESCITALOPRAM OXALATE 
Category  : Antidepressant agent  
Chemical Name : 1-[3-(Dimethylamino) propyl]-1-(4-fluorophenyl)-1, 
  3-dihydro-S-(+)-5- isobenzofurancarbonitrile oxalate 
Description : A white to off white crystalline powder. 
Molecular Structure 
                                      
 
 
Molecular Formula : C20H21FN2O•C2H2O4 
Molecular weight : Escitalopram 324.392g/mol ; 414.43 as 
 oxalate ion  
Bioavailability  : 80% 
Half life   : 27-32 hours 
Solubility  : Soluble in Dimethlyformide, in                     
Dimethylsulfoxide, Sparingly soluble in methanol & 
slightly soluble in Dichloromethane. 
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Uses:  
 Escitalopram is an antidepressant (selective serotonin reuptake inhibitor-
SSRI) used to treat depression and anxiety. It works by restoring the balance of 
certain natural substances (neurotransmitters such as serotonin) in the brain. 
Escitalopram may improve your feelings of well-being and energy level and 
decrease nervousness. 
5.2 CLINICAL PHARMACOLOGY 
Mechanism of Action 
 The mechanism of antidepressant action of escitalopram, the S-
enantiomer of racemic citalopram, is presumed to be linked to potentiation of 
serotonergic activity in the central nervous system (CNS) resulting from its 
inhibition of CNS neuronal reuptake of serotonin (5-HT). 
Pharmacodynamics 
 In vitro and in vivo studies in animals suggest that escitalopram is a 
highlyselective serotonin reuptake inhibitor (SSRI) with minimal effects on 
norepinephrine and dopamine neuronal reuptake. Escitalopram is at least 100-fold 
more potent than the R-enantiomer with respect to inhibition of 5-HT reuptake and 
inhibition of 5-HT neuronal firing rate. Tolerance to a model of antidepressant effect 
in rats was not induced by long-term (up to 5 weeks) treatment with escitalopram. 
Escitalopram has no or very low affinity for serotonergic (5-HT1-7) or other 
receptors including alpha- and beta-adrenergic, dopamine (D1-5), histamine (H1-3), 
muscarinic (M1-5), and benzodiazepine receptors. Escitalopram also does not bind to, 
or has low affinity for, various ion channels including Na+, K+, Cl-, and 
Ca++ channels. Antagonism of muscarinic, histaminergic, and adrenergic receptors 
has been hypothesized to be associated with various anticholinergic, sedative, 
and cardiovascular side effects of other psychotropic drugs. 
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Pharmacokinetics 
 The single- and multiple-dose pharmacokinetics of escitalopram are linear 
and dose-proportional in a dose range of 10 to 30 mg/day. Biotransformation of 
escitalopram is mainly hepatic, with a mean terminal half-life of about 27-32 hours. 
With once-daily dosing, steady state plasma concentrations are achieved within 
approximately one week. At steady state, the extent of accumulation of escitalopram 
in plasma in young healthy subjects was 2.2-2.5 times the plasma concentrations 
observed after a single dose. The tablet and the oral solution dosage forms of 
escitalopram oxalate are bioequivalent. 
Absorption and Distribution 
 Following a single oral dose (20 mg tablet or solution) of escitalopram, 
peak blood levels occur at about 5 hours. Absorption of escitalopram is not affected 
by food. 
 The absolute bioavailability of citalopram is about 80% relative to an 
intravenous dose, and the volume of distribution of citalopram is about 12 L/kg. 
Data specific on escitalopram are unavailable. 
 The binding of escitalopram to human plasma proteins is approximately 
56%. 
Metabolism and Elimination 
 Following oral administrations of escitalopram, the fraction of drug 
recovered in the urine as escitalopram and S-demethylcitalopram (S-DCT) is about 
8% and 10%, respectively. The oral clearance of escitalopram is 600 mL/min, with 
approximately 7% of that due to renal clearance. 
 Escitalopram is metabolized to S-DCT and S-didemethylcitalopram (S-
DDCT). In humans, unchanged escitalopram is the predominant compound in 
plasma. At steady state, the concentration of the escitalopram metabolite S-DCT in 
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plasma is approximately one-third that of escitalopram. The level of S-DDCT was 
not detectable in most subjects. In vitro studies show that escitalopram is at least 7 
and 27 times more potent than S-DCT and S-DDCT, respectively, in the inhibition 
of serotonin reuptake, suggesting that the metabolites of escitalopram do not 
contribute significantly to the antidepressant actions of escitalopram. S-DCT and S-
DDCT also have no or very low affinity for serotonergic (5-HT1-7) or other receptors 
including alpha- and beta-adrenergic, dopamine (D1-5), histamine (H1-3), muscarinic 
(M1-5), and benzodiazepine receptors. S-DCT and S-DDCT also do not bind to 
various ion channels including Na+, K+, Cl-, and Ca++ channels. 
 In vitro studies using human liver microsomes indicated that CYP3A4 
and CYP2C19 are the primary isozymes involved in the N-demethylation of 
escitalopram. 
Marked formulations : Anxiest, lexapro, cipraplex, 
seroplex,   lexamil   
Drug Interactions 
5-HT 1 agonists (eg, sumatriptan) 
 Risk of serotonin syndrome may be increased. If coadministration is 
clinically warranted, carefully observe the patient, particularly when starting 
treatment or during dose increases. 
Alcohol 
 May potentiate the effects of alcohol; use of alcohol is not advised. 
Aspirin, NSAIDs (eg, ibuprofen), warfarin 
 Risk of bleeding may be increased. Use with caution and carefully 
monitor the patient. 
      Drug Profile 
 
Department of Pharmaceutics, 
Annai Veilankanni’s Pharmacy College. 
 
48 
Beta-blockers (eg, metoprolol, propranolol) 
 Excessive beta-blockade (eg, bradycardia) may occur, increasing the risk 
of cardiac and CNS toxicity. Use with caution. 
 Buspirone, opioid analgesics (eg, meperidine), sibutramine, SNRIs 
(eg, duloxetine), St. John's wort, sympathomimetics (eg, amphetamine), 
tramadol 
 The risk of serotonin syndrome may be increased. Closely monitor 
patients. Serotonin syndrome requires immediate medical attention, including 
withdrawal of the serotonergic agent and supportive care. 
Citalopram 
 Escitalopram is the active isomer of racemic citalopram; do not 
coadminister these two agents. 
CNS drugs Use with caution. 
Cyproheptadine 
 May decrease the pharmacologic effect of escitalopram. If there is a 
decrease in the efficacy of escitalopram, consider discontinuing cyproheptadine. 
Dosage 
Usual adult dose for anxiety 
 10 mg orally once a day in the morning or evening with or without food. 
The dose may be increased to 20 mg, after a minimum of one week. 
 Escitalopram (10 to 20 mg orally daily) has been shown to be well 
tolerated and effective in the treatment of generalized anxiety disorder for up to 6 
months. 
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Usual adult dose for depression 
 10 mg orally once a day in the morning or evening with or without food. 
The dose may be increased to 20 mg, after a minimum of three weeks. 
Usual pediatric dose for depression 
12to17years: 
 10 mg orally once a day in the morning or evening with or without food. 
The dose may be increased to 20 mg, after a minimum of three weeks. 
Marketed Formulations: 
 Lexapro filim coated 5,10,20 mg tablets 
 Lexapro solution 1mg/ml 
 Cipralex 
 Seroplex 
 Anxiset  
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6. EXCIPIENTS PROFILE84-86 
 
 
6.1 MANNITOL 
 
Nonproprietary names  
 BP; PhEur; USP: Mannitol 
 JP: D-Mannitol  
Synonyms : Cordycepic acid, Manna sugar, D-mannite,  
   Mannitolum; Mannogem. 
Chemical Name : D-Mannitol  
Empirical Formula:  C6H14O6 
Structural Formula 
 
                                                         
Molecular Weight : 182.17 
Functional Category: Plasticizer, sweetening agent, tablet and capsule  
   diluent. 
Solubility  
 Freely soluble in water, soluble in alkaline solutions, slightly soluble in 
pyridine, very slightly soluble in alcohol, practically insoluble in ether. 
Excipients Profile 
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Applications in Pharmaceutical Formulation or Technology: 
 Mannitol is widely used as a diluent (10–90% w/w) in tablet formulations, 
since it is not hygroscopic and may thus be used with moisture sensitive active 
ingredients. It may be used in direct compression tablet applications, for which the 
granular and spray dried forms are available, or in wet granulations. Granulations 
containing mannitol have the advantage of being dried easily. It is commonly used 
as an excipient in the manufacture of chewable tablet formulations and also used as 
a diluent in rapidly dispersing oral dosage forms.  
Description 
 It occurs as a white, odourless, crystalline powder, or free flowing 
granules. It has a sweet taste and imparts a cooling sensation in the mouth. 
Microscopically, it appears as orthorhombic needles when crystallized from alcohol. 
                                              Mannitol grades 
Grade Description Applications 
Pearlitol 100 SD Fine particle size Excellent Diluent-binder for direct 
compression applications (Fast 
Dissolving, chewable, oral 
dispersible, effervescent tablets. 
Pearlitol 200 SD Medium particle size 
 
Incompatibilities 
 Mannitol solutions, 20% w/v or stronger, may be salted out by potassium 
chloride or sodium chloride.(19) Precipitation has been reported to occur when a 
25% w/v mannitol solution was allowed to contact plastic. Sodium cephapirin at 2 
mg/mL and 30 mg/mL concentration is incompatible with 20% w/v aqueous 
mannitol solution. Mannitol is incompatible with xylitol infusion and may form 
complexes with some metals such as aluminum, copper, and iron. Reducing sugar 
impurities in mannitol have been implicated in the oxidative degradation of a 
peptide in a lyophilized formation. 
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Safety  
 Mannitol is a naturally occurring sugar alcohol found in animals and 
plants; it is present in small quantities in almost all vegetables. Laxative effects may 
occur if mannitol is consumed orally in large quantities. If it is used in foods as a 
bodying agent and daily ingestion of over 20 g is foreseeable, the product label 
should bear the statement ‘excessive consumption may have a laxative effect’. 
6.2 CROSPOVIDONE 
Nonproprietary names  
 BP; PhEur; USP-NF: Crospovidone 
Synonyms:  
 Crospovidonum, Crospopharm, crosslinked povidone, Kollidon CL, 
Kollidon CL-M, Polyplasdone XL, Polyplasdone XL-10, Polyvinyl polypyrrolidone. 
Chemical Name : 1-Ethenyl-2-pyrrolidinone homopolymer 
Empirical Formula  
and Molecular Weight:  (C6H9NO)n >1000000 
                             
 
 
Functional Category: Tablet disintegrant 
Solubility  
 Practically insoluble in water and in most common organic solvents. 
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Applications in Pharmaceutical Formulation or Technology 
 Crospovidone is a water insoluble tablet disintegrant and dissolution agent 
used in tablets prepared by direct compression or wet and dry granulation methods. 
It can also be used as a solubility enhancer. Crospovidone can be used to enhance 
the solubility of poorly soluble drugs.  
Description 
 Crospovidone is a white to creamy white, finely divided, free flowing, 
practically tasteless, odourless, hygroscopic powder. 
Incompatibilities 
 Crospovidone is compatible with most organic and inorganic 
pharmaceutical ingredients. When exposed to a high water level 
Stability and Storage Conditions 
 Since crospovidone is hygroscopic, it should be stored in an airtight 
container in a cool, dry place. 
Crospovidone grades 
Grade Description Applications 
Kollidon CL Standard Grade Used as a super disintegrant in tablets for 
improving release of active substances  
Kollidon CL-F Fine particle size Fine Grade is ideal for small tablets 
Kollidon CL-SF 
KollidonCL-M 
Super fine Grade 
Micronized Grade 
Micronized Grade is used as a stabilizer for 
suspensions 
. 
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6.3 CELLULOSE, MICROCRYSTALLINE 
Nonproprietary names 
 BP; JP; PhEur; USP-NF: Microcrystalline Cellulose 
Synonyms:  
 Avicel PH, Cellulose gel, Hellulosum microcristallinum, Ceolus KG, 
Crystalline cellulose, Emcocel, Fibrocel, Pharmacel, Tabulose. 
Chemical Name: Cellulose  
Empirical Formula and Molecular Weight: (C6H10O5)n; 36 000  where n -220. 
 
 
 
 
 
Functional Category:  
 Adsorbent, suspending agent, tablet and capsule diluent, tablet 
disintegrant. 
Solubility 
 Slightly soluble in 5% w/v sodium hydroxide solution; practically 
insoluble in water, dilute acids, and most organic solvents. 
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Applications in Pharmaceutical Formulation or Technology 
 It is as a binder/diluent in oral tablet and capsule formulations in both wet 
granulation and direct compression processes. In addition it also has some lubricant 
and disintegrant properties. 
Description 
 Microcrystalline cellulose is a purified, partially depolymerised cellulose 
that occurs as a white, odourless, tasteless, crystalline powder composed of porous 
particles. It is commercially available in different particle sizes and moisture grades 
that have different properties and applications. 
6.4 ASPARTAME  
Nonproprietary names 
 BP; PhEur; USP-NF: Aspartame 
Synonyms: 
  Aspartamum, Aspartyl phenylamine methyl ester, Natra Taste, 
NutraSweet, Pal Sweet, Pal Sweet Diet. 
Chemical Name : N-L-a-Aspartyl-L-phenylalanine 1-methyl ester  
Empirical Formula  
and Molecular weight:  C14H18N2O5; 294.30 
Molecular Structure 
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Functional category: Sweetening agent. 
Solubility 
 Slightly soluble in ethanol (95%), sparingly soluble in water. 
Applications in Pharmaceutical Formulation or Technology  
 It is used as a sweetening agent in tablets, powder mixes, and vitamin 
preparations. The approximate sweetening power is 180–200 times that of sucrose. 
Unlike some other intense sweeteners, aspartame is metabolized in the body and 
consequently has some nutritive value: 1 g provides approximately 17 kJ (4 kcal). 
Description 
 It occurs as an off white, almost odourless crystalline powder with an 
intensely sweet taste. 
6.5 TALC 
Nonproprietary Names 
 BP: Purified Talc 
 JP, PhEur USP: Talc 
Synonyms 
 Altalc; E553b; hydrous magnesium calcium silicate; hydrous magnesium 
silicate; Imperial; Luzenac Pharma; magnesium hydrogen metasilicate; Magsil 
Osmanthus; Magsil Star; powdered talc; purified French chalk; Purtalc; soapstone; 
steatite; Superiore; talcum. 
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Chemical Name and CAS Registry Number:  Talc [14807-96-6] 
Empirical Formula and Molecular Weight 
 Talc is a purified, hydrated, magnesium silicate, approximating to the 
formula Mg6(Si2O5)4(OH)4.  
 It may contain small, variable amounts of aluminum silicate and iron. 
Functional Category 
 Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule 
lubricant. 
Applications in Pharmaceutical Formulation or Technology 
 Talc was once widely used in oral solid dosage formulations as a lubricant 
and diluent, , although today it is less commonly used. However, it is widely used as 
a dissolution retardant in the development of controlled-release products. Talc is 
also used as a lubricant in tablet formulations; in a novel powder coating for 
extended-release pellets; and as an adsorbant. In topical preparations, talc is used as 
a dusting powder, although it should not be used to dust surgical gloves. Talc is a 
natural material; it may therefore frequently contain microorganisms and should be 
sterilized when used as a dusting powder. Talc is additionally used to clarify liquids 
and is also used in cosmetics and food products, mainly for its lubricant properties. 
Uses of talc. 
Use Concentration (%) 
Dusting powder 90.0–99.0 
Glidant and tablet lubricant 1.0–10.0 
Tablet and capsule diluents 5.0–30.0 
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Description 
 Talc is a very fine, white to grayish-white, odourless, impalpable, 
unctuous, crystalline powder. It adheres readily to the skin and is soft to the touch 
and free from grittine 
Stability and Storage Conditions 
 Talc is a stable material and may be sterilized by heating at 1608C for not 
less than 1 hour. It may also be sterilized by exposure to ethylene oxide or gamma 
irradiation. Talc should be stored in a well-closed container in a cool, dry place. 
6.6 HYDROXYPROPYL CELLULOSE, LOW-SUBSTITUTED 
Non-proprietary Names 
 JP: Low Substituted Hydroxypropylcellulose 
 USP-NF: Low-Substituted Hydroxypropyl Cellulose 
Synonyms 
 Cellulose, 2-hydroxypropyl ether; 2-hydroxypropyl ether (lowsubstituted) 
cellulose; hyprolose, low-substituted; L-HPC; oxypropylated cellulose. 
Chemical Name and CAS Registry Number 
 Cellulose, 2-hydroxypropyl ether (low-substituted) [9004-64-2] 
Empirical Formula and Molecular Weight 
 The USP32–NF27 describes low-substituted hydroxypropyl cellulose as 
low-substituted hydroxypropyl ether of cellulose. Compared to hydroxypropyl 
cellulose, low-substituted hydroxypropyl cellulose has only a small proportion of the 
three free hydroxyl groups per glucose subunit converted to a hydroxypropyl ether. 
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When dried at 1058C for 1 hour, it contains not less than 5.0% and not more than 
16.0% of hydroxypropoxy groups (—OCH2CHOHCH3). Low-substituted 
hydroxypropyl cellulose is commercially available in a number of different grades 
that have different particle sizes and substitution levels. 
                                      
 
 
Functional Category 
 Tablet and capsule disintegrant; tablet binder. 
Applications in Pharmaceutical Formulation or Technology 
 Low-substituted hydroxypropyl cellulose is widely used in oral 
solid-dosage forms. It is primarily used as a disintegrant, and as a 
binder for tablets and granules in wet or dry granulation.  
 It has been used in the preparation of rapidly disintegrating tablets 
produced by direct compression methods.  
 In addition, low substituted hydroxypropyl cellulose has been used 
as a binder/ disintegrant included in the powder layering process on 
spherical cores and to prepare pellets by extrusion/spheronization.  
 Low particle size and high hydroxypropyl content is recommended 
to produce round spheres and rapid dissolution.  
 There are a number of grades that have different particle sizes and 
substitution levels.  
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 LH-11 has the longest fibrous particles, and is typically used as an 
ant capping agent and disintegrant for direct compression.  
 LH-21 is less fibrous and is used as a binder and disintegrant for 
tablets through the wet-granulation process.  
 LH-31 is a small-particle grade used especially for extrusion to 
produce granules, as it has a small particle size that is better for 
passing a screen. 
 LH-B1 is the nonfibrous, high-density grade designed for fluid-bed 
granulation, and can be used for direct compression and/ or 
formulations with a high low-substituted hydroxypropyl cellulose 
loading. Lower substitution grades  
 LH-22 and LH-32 can be used for better disintegration capability, 
depending on the characteristics of the active ingredients. The 
typical content of low-substituted hydroxypropyl cellulose in a 
formulation is approximately 5–50%. 
Description 
 Low-substituted hydroxypropyl cellulose occurs as a white to yellowish 
white powder or granules. It is odourless or has a slight, characteristic odor, and it is 
tasteless 
Stability and Storage Conditions 
 Low-substituted hydroxypropyl cellulose is a stable, though hygroscopic, 
material. The powder should be stored in a well closed container 
Colloidal Silicon Dioxide 
Nonproprietary Names 
 BP: Colloidal Anhydrous Silica 
 JP: Light Anhydrous Silicic Acid 
 PhEur: Silica, Colloidal Anhydrous 
 USP-NF: Colloidal Silicon Dioxide 
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Synonyms 
 Aerosil; Cab-O-Sil; Cab-O-Sil M-5P; colloidal silica; fumed silica; fumed 
silicon dioxide; hochdisperses silicum dioxid; SAS; silica colloidalis anhydrica; 
silica sol; silicic anhydride; silicon dioxide colloidal; silicon dioxide fumed; 
synthetic amorphous silica; 
Chemical Name and CAS Registry Number: Silica [7631-86-9] 
Empirical Formula and Molecular Weight:  SiO2 60.08 
Functional Category 
 Adsorbent; ant caking agent; emulsion stabilizer; glidant; suspending 
agent; tablet disintegrant; thermal stabilizer; viscosity-increasing agent.  
Applications in Pharmaceutical Formulation or Technology 
 Colloidal silicon dioxide is widely used in pharmaceuticals, 
cosmetics, and food products 
 .Its small particle size and large specific surface area give it 
desirable flow characteristics that are exploited to improve the flow 
properties of dry powders in a number of processes such as 
tableting and capsule filling.  
 Colloidal silicon dioxide is also used to stabilize emulsions and as a 
thixotropic thickening and suspending agent in gels and semisolid 
preparations. With other ingredients of similar refractive index, 
transparent gels may be formed. The degree of viscosity increase 
depends on the polarity of the liquid  
 In aerosols, other than those for inhalation, colloidal silicon dioxide 
is used to promote particulate suspension, eliminate hard settling, 
and minimize the clogging of spray nozzles.  
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 Colloidal silicon dioxide is also used as a tablet disintegrant and as 
an adsorbent dispersing agent for liquids in powders.  
 Colloidal silicon dioxide is frequently added to suppository 
formulations containing lipophilic excipients to increase viscosity, 
prevent sedimentation during molding, and decrease the release 
rate.  
 Colloidal silicon dioxide is also used as and adsorbent during the 
preparation of wax microspheres; as a thickening agent for topical 
preparations; and has been used to aid the freeze-drying of 
nanocapsules and nanosphere suspensions.  
 Uses of colloidal silicon dioxide. 
Use Concentration (%) 
Aerosols 0.5–2.0 
Emulsion stabilizer 1.0–5.0 
Glidant 0.1–1.0 
Suspending and thickening agent 2.0–10.0 
 
Description 
 Colloidal silicon dioxide is sub microscopic fumed silica with a particle 
size of about 15 nm. It is a light, loose, bluish-white-colored, odourless, tasteless, 
amorphous powder. 
6.7 KYRONT-3185 
Synonyms:  
 Kyron T-314 is derived from cross linked polymer of Polycarboxylic 
acids as per USP/NF & has the K+ ionic form. It is a very high purity polymer used 
in pharmaceutical formulations as a super fast disintegrant as well as dissolution 
improver in solid dosage forms like tablets, capsules, pellets etc. It is available in 
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white free flowing powder hence it is suitable for the both wet granulation as well as 
direct compression system for tablet formulations. 
APPLICATIONS 
As Disintegrating agent: 
 Kyron T-314 has a very high swelling tendency of hydration either in 
contact with water or G.I. fluids causing fast disintegration without the formation of 
lumps and thus acts as an effective tablet super disintegrant. Required quantity is 
from 0.5% to 4.0% to get fast disintegration. 
As Dissolution Improver:  
 Kyron T-314 breaks the tablets into very smaller particles, thus it 
increases the effective surface area for the absorption of the active substances and 
thus it increases the dissolution and bioavailability of the active substances. 
Required quantity is from 2.0% to 6.0% for dissolution improvement. 
 Rapid disintegrating agent 
 Elimination of lump formation 
 Compatible with all therapeutic agents and excipients 
 Imparts excellent strength to the tablets 
 Elimination of the sticking problems to the dies and punch 
 Improves bioavailability of the drug 
 Uniformly mix with low dose tablets blend or formulations 
 Smooth surface after storage 
 Provide smooth cream-like mouth feel, so more suitable for ODT 
 Suitable for both direct compression and wet granulation methods 
 Cost effective 
 White in color 
 Directly compressible grade 
 Dissolution improver 
 Effective at very low concentration (0.5 to 4.0%). 
 
Excipients Profile 
 
Department of Pharmaceutics, 
Annai Veilankanni’s Pharmacy College. 
 
64 
Toxicity 
 Kyron T-314 is high molecular weight polymer, so doesn't get absorbed 
by body tissue and is safe for human consumption. It has no physiological action at 
recommended dosage and it is non toxic. 
Storage 
 Store in tightly closed container. Keep away from moisture. If moisture is 
absorbed then dry at 90°C to 100°C to remove moisture content and make it below 
10%. 
6.8 PROSOLV ODT 86 
 PROSOLV ODT is an orally disintegrating tablet Excipient matrix. It 
allows a rapid formulation development and quality tablet manufacture. 
 PROSOLV ODT addresses formulation and manufacturing challenges 
with robust functional performance required for high speed tablet manufacture. 
Patients experience a tablet with pleasing mouth feel and fast disintegration in the 
oral cavity without needing water. With no licensing and, royalty agreements 
required, JRS PHARMA makes PROSOLV ODT ready to use for scientists, 
manufacturing, and business professionals alike. 
 PROSOLV ODT is simple-to-use co-processed composite derived from 
JRS PHARMA's patented PROSOLV Technology. Its primary application is for 
the development and manufacture of orally disintegrating tablets allowing the 
discrete and convenient administering of medicines without water for high patient 
compliance. 
Offering Advantages for 
 Formulation Development 
 Manufacturing Ease 
 Business Simplicity 
 Patient Compliance 
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INGREDIENTS CONCENTRATION 
         Microcrystalline Cellulose 15-30% 
Colloidal Silicon Dioxide 1.5-2.5% 
Mannitol 30-40% 
Fructose 30-40% 
Crospovidone 4-6% 
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7. MATERIALS AND METHODS 
 
7.1 LIST OF EQUIPMENTS: 
Table -7.1 List of equipments used 
Equipment Manufacturer Model 
Electronic single pan balance Sartorius Essae LA1205 TE2145 
Mechanical Sifter with sieve 40 
and 60 
Retsec AS100 
Tapped Density apparatus Electro lab ETD 1020 
 LOD Satorious MAB5 
Analytical Sieve Shaker Retsec AS200 
Blender Rimec 410AG 
Compression Machin Chamundi Pharma 
Machinery 
PPM406300210 
Friabilator Electro lab Ef-2 
Dissolution Apparatus Electro lab TDTO8L 
Ultra voilet-visible spectroscopy  UV 2400PC 
series 
Disintegration Apparatus Electro Lab ED2AL 
Moisture analyzer Sartorius  --- 
pH meter Eutech cyber scan 
100 
--- 
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7.2 LIST OF CHEMICALS: 
Table7.2 List of chemicals used 
Ingredients Supplier 
. Escitalopram Oxalate Hetero Drugs Limited, Hyderabad 
Cross Povidone CL-F Shanhung Industries Co.Ltd 
LHPC-21 SGN ETSU Chemicals Co.Ltd 
Kyron T314 Coral pharma 
Aspartame Newtrasweet company, Augusta 
Orange Frimerich 
Peppermint Frimerich 
Lake sunset yellow Amerind colors & Chemicals pvt.ltd 
Aerosil Wacker Chemicals 
Prosolv ODT  JRS Pharma Pvt Ltd 
MCC (Cyclocel pH112) FMC Biopolymer 
Mannitol SD200 (Peritol) Merck Pvt.Ltd 
Talc Analyst, Udaipur, India  
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7.3 PREFORMULATION STUDIES   
API CHARACTERIZATION 
Identification of Escitalopram oxalate By UV Spectroscopy  
 25mg of Escitalopram oxalate standard dissolved in 100 ml of methanol and 
further diluted and scanned in the UV region. 
Bulk Density1: 
 It’s a measurement to describe packing of particles. Bulk density/apparent 
density is used to determine the amount of drug that occupies the volume (gm/ml). 
                                
 
Determination of Bulk density: 
 Weighed quantity of Escitalopram Oxalate (25gm) was transferred into 100 
ml measuring cylinder without tapping during transfer. The volume occupied by the 
drug was measured. Bulk density was measured by using formula b = m / Vb. The 
values obtained are reported in the table. 
Tapped density87: 
 25 gm of Escitalopram Oxalate was taken in 100 ml measuring cylinder that 
was placed in Electro lab tapped density apparatus (method USP-I). Initial volume 
(V0) of the cylinder was noted and then the cylinder was tapped 500 times and 
volume was measured. Then further an additional 750 tapings were repeated. No 
difference was noted between the volumes of the two tapings (500 and 750). The 
final volume (V)
 
was considered after completion of 750 taps.  Tapped density was 
measured by using formula t = m / Vt. The values obtained are reported in the table. 
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Compressibility Index87, 88: 
 Weighed amount of Escitalopram Oxalate (25gm) was transferred to 100ml-
graduated cylinder and subjected to 500,750 &1250 taps in tap density tester 
(Electro lab). The difference between two taps should be less than 2%. The % of 
compressibility index calculated using formula  
 Compressibility Index = 100 * (tapped -bulk) / tapped 
Hausner’s ratio87: 
 It is measurement of frictional resistance of the drug .the ideal range should 
be 1.2 –1.5.it is the determined by the ratio of tapped density and bulk density. 
 Hausners ratio = tapped / bulk 
Table7.3 Scale of Flow ability 
Compressibility index (%) Flow character Hausner Ratio 
10 Excellent 1.00 – 1.11 
11 – 15 Good 1.12 – 1.18 
16 – 20 Fair 1.19 – 1.25 
21 – 25 Passable 1.26 – 1.34 
26 – 31 Poor 1.35 – 1.45 
32 – 37 Very poor 1.46 – 1.59 
>38 Very, very poor >1.60 
 
Angle of repose87: 
 It is defined as the maximum angle that can be obtained between the free 
standing of powder heap and horizontal plane, which is given by the equation: 
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Angle of  repose  1 heigh of thepiletan
radius of thepile
    
 
Procedure: Weighed quantity of the drug was passed through a funnel kept at a 
height 2 cm from the base. The powder is passed till it forms a heap and touches the 
tip of the funnel. The radius was measured and angle of repose was calculated by 
using the above formula.        
Table 7.4 Flow properties and corresponding angle of repose 
Flow Property Angle of Repose (degrees) 
Excellent 25 – 30 
Good 31 – 35 
Fair – aid not needed 36 – 40 
Passable – may hang up 41 – 45 
Poor - must agitate, vibrate 46 – 55 
Very poor 56 – 65 
Very, very poor >66 
 
 From the above results it is evident that the drug has  poor flow properties, as 
the compressibility index, Hausner’s ratio and Angle of repose values are high.  
Loss on drying (LOD):  
1 gm of the drug was placed in the LOD apparatus and percentage loss on 
drying was observed. 
Melting point: melting point was observed by capillary tube method. 
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7.4 DRUG EXCIPIENT COMPATIBILITY STUDIES 
 Drug-Excipient compatibility studies lay the foundation for designing a 
chemically stable formulation for clinical and commercial development. Drug 
excipient compatibility studies are conducted during preformulation to select the 
most appropriate excipients. 
 Objective To study compatibility of the active ingredients with 
selected excipients and to prove that the selected excipients are compatible with the 
active ingredient. 
Table 7.5 Compatibility study ratio for solid dosage forms 
S.NO Ingredients Ratio 
1 Escitalopram oxalate  
2 Escitalopram oxalate + LHPC-21 1:1 
3 Escitalopram oxalate + Crospovidone CL-F 1:1 
4 Escitalopram oxalate + Kyron T-314 1:1 
5 Escitalopram oxalate + Aspartame  1:0.05 
6 Escitalopram oxalate + Powdarome pippermint 1:0.05 
7 Escitalopram oxalate + Powdarome orange 1:0.05 
8 Escitalopram oxalate + Lake Sunset Yellow 1:0.05 
9 Escitalopram oxalate + Aerosil 1:0.25 
10 Escitalopram oxalate + MCC pH 112 1:10 
11 Escitalopram oxalate + Mannitol  1:10 
12 Escitalopram oxalate + Talc 1:0.05 
 The active ingredients and the excipients were mixed in the selected 
ratios using a mortor and pestle. The mixtures are transferred into glass vials and 
sealed. The samples were placed as first set of initial samples and second set of 
samples were kept at 40C±2C/75%±5 % RH for 4 weeks. The samples were 
analyzed for physical parameters.  
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 Drug and excipients were weighed accurately in the above ratios and 
well by using motor and pestle this was transferred into a glass vials. Vials were 
closed using rubber stopper and labeled the condition and stored in respective 
conditions 40C±2C/75%±5 % RH for 4 weeks. The samples were withdrawn 
every week and analyzed for physical parameters.  
Standard calibration curve of the Escitalopram oxalate 
 25mg of the dug was dissolved in the 50ml of methanol and sonicated for 
few minutes and further diluted to 100ml with methanol. From this above solution 
futher dilutions were carried out to obtained 2,4,6,8,10 µg/ml using methanol. The 
absorbance of the above concentration was measured at 239nm using UV 
spectroscopy. 
Formulation of Escitalopram oxalate tablets  
 As the amount of drug substance weighed may not be equivalent to the 
desired weight (because of the presence of moisture).Therefore the quantity of 
substance to be weighed was calculated as follows; 
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Table 7.7 Formulation Developmental Trails 
 Excipients /Formulations  F1 F2 F3 F4 F5 F6 F7 F8 F9 
Escitalopram Oxalate  20 20 20 20 20 20 20 20 20 
Crospovidone CL-F 5 5 10 10 10 10 10 10 10 
LHPC-21 5 5 10 10 10 10 10 10 10 
Kyron T314 0 10 15 15 15 15 15 15 15 
aspartame  5 5 5 5 5 5 5 5 5 
orange  5 8 8 8 8 8 8 8 8 
Peppermint 0 8 8 8 8 8 8 8 8 
Lake sunset yellow 1 1 1 1 1 1 1 1 1 
Aerosil 20 20 20 20 0 5 15 20 20 
Prosolv ODT 0 0 0 0 120 65 25 0 0 
MCC(CyclocelpH112) 136 81 50 40 0 0 0 0 0 
Mannitol SD200(Peritol) 0 40 50 60 0 50 80 100 100 
Talc 3 3 3 3 3 3 3 3 3 
Total weight(mg) 200 200 200 200 200 200 200 200 200 
 
Note: Quantities in mg 
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                  Figure -7.1 MANUFACTURING PROCESS  
 
 
 
 
 
 
 
7.5 NARRATIVE DESCRIPTION OF MANUFACTURING PROCESS 
 Formulation of oral disintegrating tablets of Escitalopram oxalate20 mg was 
carried out by direct compression technique 
Procedure for F1 
 Escitalopram oxalate, Crospovidone CL-F, LHPC-21, Aspartame, 
Powdarome     Orange& Aerosil were weighed and sifted through #40 
mesh.  
 Lake sunset yellow was shifted separately through 80# mesh. 
 Micro crystalline cellulose pH112 was shifted separately through 40# 
mesh. 
 Above three blends was co shifted through 40# mesh and  then blended 
in poly bag for 10 mins 
 The lubricant, Talc was shifted through 40 # separately and added to 
the above blend. 
Sifted materials 
 
Lubricated blend 
1. Physical 
parameters 
2. Drug release 
3. Assay  
4. Moisture uptake 
study. 
5. Stability study 
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 The final blend was mixed thoroughly in polythene bag for 10-15 mins 
and compressed under 8mm flat bowled edge punches. 
Procedure for F2 
 In this formula different formulas were assumed with different 
concentrations of flavours and sweeteners for their optimisation. The below 
procedure was followed for the preparation of the blend and taste was evaluated. 
 Escitalopram oxalate, Crospovidone CL-F, LHPC-21, Aspartame, 
KyronT314, Powdarome Orange & Aerosil were weighed and sifted 
through #40 mesh.  
 Lake sunset yellow was shifted separately through 80# mesh. 
 Micro crystalline cellulose pH112 was shifted separately through 40# 
mesh. 
 Mannitol SD200 was shifted separately through 40# mesh 
 Above blends was co shifted through 40# mesh and  then blended in 
poly bag for 10 mins. 
 The lubricant, Talc was shifted through 40 # separately and added to 
the above blend. 
 The final blend was mixed thoroughly in polythene bag for 10-15 mins. 
 
 Above blends were prepared with different concentrations of powdarome 
orange, aspartame and powdarome peppermint. 
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Table 7.8 Optimizing concentrations of flavours 
 Trail-A Trail-B Trail-C Trail-D 
Escitalopram Oxalate  20 20 20 20 
Crospovidone CL-F 5 5 5 5 
LHPC-21 5 5 5 5 
Kyron T314 10 10 10 10 
Aspartame  5 5 5 5 
Orange  0 5 5 8 
Peppermint 0 0 5 8 
lake sunset yellow 1 1 1 1 
Aerosil 20 20 20 20 
Prosolv ODT 0 0 0 0 
MCC(CyclocelpH112) 91 86 81 75 
Mannitol 
SD200(Peritol) 40 40 40 40 
Talc 3 3 3 3 
Total weight 200 200 200 200 
 
 As the different concentrations was prepared and taste was evaluated and 
therefore finally Trail-D was considered as the best among the four trails and the 
blend was used for the compression of tablets using 8mm flat bowled edge punches. 
Procedure for F3 
 Escitalopram oxalate, Crospovidone CL-F, LHPC-21, Aspartame, 
KyronT314, Powdarome Orange, powdarome peppermint & Aerosil 
were weighed and sifted through #40 mesh.  
 Lake sunset yellow was shifted separately through 80# mesh. 
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 Micro crystalline cellulose pH112 was shifted separately through 40# 
mesh. 
 Mannitol SD200 was shifted separately through 40# mesh 
 Above blends was co shifted through 40# mesh and  then blended in 
poly bag for 10 mins 
 The lubricant, Talc was shifted through 40 # separately and added to 
the above blend. 
 The final blend was mixed thoroughly in polythene bag for 10-15 mins 
and compressed under 8mm flat bowled edge punches. 
Procedure for F4 
 Escitalopram oxalate, Crospovidone CL-F, LHPC-21, Aspartame, 
KyronT314, Powdarome Orange, powdarome peppermint & Aerosil 
were weighed and sifted through #40 mesh.  
 Lake sunset yellow was shifted separately through 80# mesh. 
 Micro crystalline cellulose pH112 was shifted separately through 40# 
mesh. 
 Mannitol SD200 was shifted separately through 40# mesh 
 Above blends was co shifted through 40# mesh and  then blended in 
poly bag for 10 mins 
 The lubricant, Talc was shifted through 40 # separately and added to 
the above blend. 
 The final blend was mixed thoroughly in polythene bag for 10-15 mins 
and compressed under 8mm flat bowled edge punches. 
Procedure for F5 
 Escitalopram oxalate, Crospovidone CL-F, LHPC-21, Aspartame, 
KyronT314, Powdarome Orange& powdarome peppermint were 
weighed and sifted through #40 mesh.  
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 Lake sunset yellow was shifted separately through 80# mesh. 
 Prosolv ODT was shifted separately through 40# mesh. 
 Above blends was co shifted through 40# mesh and  then blended in 
poly bag for 10 mins 
 The lubricant, Talc was shifted through 40 # separately and added to 
the above blend. 
 The final blend was mixed thoroughly in polythene bag for 10-15 mins 
and compressed under 8mm flat bowled edge punches. 
Procedure for F6 
 Escitalopram oxalate, Crospovidone CL-F, LHPC-21, Aspartame, 
KyronT314, Powdarome Orange, powdarome peppermint  & Aerosil 
were weighed and sifted through #40 mesh.  
 Lake sunset yellow was shifted separately through 80# mesh. 
 Mannitol SD200 was shifted separately through 40# mesh 
 Prosolv ODT was shifted separately through 40# mesh. 
 Above blends was co shifted through 40# mesh and  then blended in 
poly bag for 10 mins 
 The lubricant, Talc was shifted through 40 # separately and added to 
the above blend. 
 The final blend was mixed thoroughly in polythene bag for 10-15 mins 
and compressed under 8mm flat bowled edge punches. 
Procedure for F7 
 Escitalopram oxalate, Crospovidone CL-F, LHPC-21, Aspartame, 
KyronT314, Powdarome Orange, powdarome peppermint & Aerosil 
were weighed and sifted through #40 mesh.  
 Lake sunset yellow was shifted separately through 80# mesh. 
 Mannitol SD200 was shifted separately through 40# mesh 
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 Prosolv ODT was shifted separately through 40# mesh. 
 Above blends was co shifted through 40# mesh and  then blended in 
poly bag for 10 mins 
 The lubricant, Talc was shifted through 40 # separately and added to 
the above blend. 
 The final blend was mixed thoroughly in polythene bag for 10-15 mins 
and compressed under 8mm flat bowled edge punches. 
Procedure for F8 
 Escitalopram oxalate, Crospovidone CL-F, LHPC-21, Aspartame, 
KyronT314, Powdarome Orange, powdarome peppermint & Aerosil 
were weighed and sifted through #40 mesh.  
 Lake sunset yellow was shifted separately through 80# mesh. 
 Mannitol SD200 was shifted separately through 40# mesh. 
 Above blends was co shifted through 40# mesh and  then blended in 
poly bag for 10 mins 
 The lubricant, Talc was shifted through 40 # separately and added to 
the above blend. 
 The final blend was mixed thoroughly in polythene bag for 10-15 mins 
and compressed under 8mm flat bowled edge punches. 
Procedure for F9  
 Reproducibility batch for F8 
7.6 PRE-COMPRESSION PARAMETERS89 
ANGLE OF REPOSE 
 The internal angle between the surface of the pile of blend and the horizontal 
surface is known as the angle of repose. 
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Method 
 The Angle of repose was known by passing the blend through a funnel fixed 
to a burette stand at a particular height (4 cm). A graph paper was placed below the 
funnel on the table. The height and radius of the pile was measured. Angle of repose 
of the blend was calculated using the formula. 
                      
BULK DENSITY 
 Bulk density is used as a measure to describe packing materials or granules. 
Method  
 Bulk density is the ratio of given mass of powder and its bulk volume. It was 
determined by transferring an accurately weighed amount of powder sample to the 
graduated cylinder with the aid of a funnel. The initial volume was noted. Ratio of 
weight of the sample to the volume it occupied was calculated.      
                            
TAPPED DENSITY 
Method  
  Tapped density was measured by transferring a known quantity of blend into 
a graduated cylinder and was placed on the tapped density apparatus. The initial 
volume was noted. The apparatus was set for 500, 750 and 1250 taps. The tapped 
density was determind as the ratio of mass of the blend to the tapped volume. 
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COMPRESSIBILITY INDEX 
                              It is the propensity of a powder to be compressed. 
Method 
 It is measured by tapped density apparatus for 500, 750 and 1250 taps 
for which the difference should be not more than 2%. Based on the apparent bulk 
density and tapped density the percentage compressibility of the blend was 
determined using the following formula.   
              
 
HAUSNER RATIO 
 It indicates the flow properties of the powder. The ratio of tapped 
density to the bulk density of the powders is called Hausner ratio. 
                                        
                       Table 7.9 Flow properties and Compressibility index 
 
S No. 
Flow 
Properties 
Angle  of 
Repose  (è) 
Compressibility        
Index    (%) 
Hausner 
Ratio 
1 Excellent       25-30              <10   1.0-1.11 
2 Good       31-35              11-15   1.12-1.18 
3 Fair       36-40              16-20   1.19-1.25 
4 Possible       41-45              21-25   1.26-1.34 
5 Poor       46-55              26-31   1.35-1.45 
6 Very poor       56-65              32-37   1.46-1.59 
7 Very very poor        >66               >38     >1.60 
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7.7 POST COMPRESSION PARAMETERS 
PHYSICAL APPEARANCE  
 The physical appearance of the compressed tablets involves the measurement 
of a number of attributes like tablet shape, smoothness, chipping, cracks, surface 
texture, colour etc. 
THICKNESS  
 Thickness was determined for 20 pre-weighed tablets of each batch using a 
digital vernier scale and the average thickness was determined in mm. The tablet 
thickhness should be controlled within a ± 5% variation of a standard. 
WEIGHT VARIATION  
 20 tablets were selected randomly from a batch and were individually 
weighed and then the average weight was calculated. The tablets meet the USP 
specifications if not more than 2 tablets are outside the percentage limit and if no 
tablet differs by more than 2 times the percentage limits. 
Average weight of tablet (mg) % difference 
130 or less 10 % 
From 130 to 324 7.5% 
> 324 5% 
 
HARDNESS TEST 
 The crushing load which is the force required to break the tablet in the radial 
direction was measured using a Schluenzier hardness tester. The hardness of 10 
tablets was noted and the average hardness was calculated. It is given in kp or 
kg/cm2.  
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PERCENTAGE FRIABILITY 
 In friability testing the tablets are subjected to abrasion and shock. It gives an 
indication of the tablets ability to resist chipping and abrasion during transportation 
and shipping.  
Method  
 If the tablet weight is ≥ 650 mg 10 tablets were taken and initial weight was 
noted. For tablets of weight less than 650 mg the number of tablets equivalent to a 
weight of 6.5 g were taken. The tablets were rotated in the Roche Friabilator for 100 
revolutions at 25 rpm. The tablets were dedusted and reweighed. The percentage 
friability should be not more than 1%w/w of the tablets being tested. 
 The percentage friability is expressed as the loss of weight and is calculated 
by the formula: 
 
DISINTEGRATION TIME 
 Disintegration time is the time taken by the tablet to breakup into smaller 
particles. The disintegration test is carried out in an apparatus containing a basket 
rack assembly with six glass tubes of 7.75 cm in length and 2.15 mm in diameter, 
the bottom of which consists of a #10 mesh sieve. The basket is raised and lowered 
28-32 times per minute in a medium of 900 ml which is maintained at 37±20C. Six 
tablets were placed in each of the tubes and the time required for complete passage 
of tablet fragments through the mesh (# 10) was considered as the disintegration 
time of the tablet. The disintegration time that patients can experience for oral 
disintegrating tablets ranges from 5 to 30seconds. 
 
Materials and Methods 
 
Department of Pharmaceutics, 
Annai Veilankanni’s Pharmacy College. 
 
84 
Wetting time and water absorption ratio: 
 Wetting time of dosage form is related to with the contact angle. Wetting 
time of the ODT is another important parameter, which needs to be assessed to give 
an insight into the disintegration properties of the tablet. Lower wetting time implies 
a quicker disintegration of the tablet. The wetting time of the tablets can be 
measured by using the simple procedure55. Five circular tissue papers of 10cm 
diameter are placed in a petridish. Ten milliliters of water soluble dye solution is 
added to petridish. A tablet is carefully placed on the surface of the tissue paper. The 
time required for water to reach upper surface of the tablet is noted as the wetting 
time. For measuring water absorption ration the weight of the tablet before keeping 
in the petridish is noted (Wb). The wetted tablet from the petridish is taken and 
reweighed (Wa). The water absorption ratio,R can be the determined according to 
the following equation. 
 R = 100 (Wa-Wb) / Wb 
                                                                                          
 
 
 
In vitro dispersion time  
 In vitro dispersion time was measured by dropping a tablet in a glass cylinder 
containing 6 ml of Sorenson’s buffer (pH6.8). Six tablets from each formulation 
were randomly selected and  in vitro dispersion time was performed. 
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DISSOLUTION STUDIES 
 Dissolution is a process by which the disintegrated solid solute enters the 
solution. The test determines the time required for a definite percentage of the drug 
in a tablet to dissolve under specified conditions. 
Method 
 The dissolution test was carried out in USP Apparatus Type II (paddle) with 
0.1 N Hydrochloric acid as the dissolution medium. The samples were drawn at 5, 
10, 15  and 30 min. Fresh volume of the medium were replaced with the withdrawn 
volume to maintain the sink conditions. Samples withdrawn were analyzed for the 
percentage of drug released. 
 
Dissolution Parameters 
Dissolution Apparatus : USP Apparatus Type II (Paddle) 
Dissolution Medium  : 0.1N Hydrochloric acid 
Volume                          : 900 ml 
Temperature                 : 37±2 C 
 Rpm                                : 50    
Sampling Intervals (min) : 5, 10, 15&30min 
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Assay: 
 About 6 tablets were grinded to fine powder in a dry mortar and a quantity of 
powder equavalent to 100mg of Escitalopram Oxalate was transferred into 100ml 
volumetric flask. To this 50ml of methanol was added and sonicated to dissolve the 
drug and diluted to volume with methanol and mixed thoroughly. The solution was 
filtered through what man filter paper no 1.and futher diluted to get a requied ppm 
UV parameters: 
 Instrument Type : UV – 2400PC series 
 Measuring mode : Absorbance 
 Wavelength range : 200.00nm to 300.00nm 
 Scan speed  : Medium 
 Slit width  : 2.0nm 
  
Calculation 
 
STABILITY STUDIES 
 The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety of 
environmental factors, such as temperature, humidity etc. 
Objective:  
 To generate documented evidence that the tablets manufactured comply with 
the finished product specifications under accelerated and long term stability 
conditions as per ICH guidelines. 
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Design Plan 
 Accelerated study: The product is subjected to accelerated stability studies at 
40C±2C/75% ±5% RH for 6 months. 
 Long term study: The product is subjected to long term studies at 
25C±2C/60% ±5%RH for 12 months 
 
 
Table 7.9 Stability Sampling withdrawl schedule 
S.NO. STORAGE CONDITION TEST PERIOD 
1. 40C±2C/75% ±5% RH 
1st  month 
2nd month 
3 months 
6 months 
2. 25C±2C/60% ±5% RH 
3 months 
6 months 
9 months 
12 months 
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8. RESULTS AND DISCUSSION 
8.1 API CHARACTERIZATION 
 
 
 
 
 
 
 
 
Figure-8.1 UV Spectroscopy of Escitalopram oxalate API 
 The Escitalopram Oxalate API (10µg/ml) was scanned in the UV between 
200-400nm observed that at 239 nm shows maximum absorbance.  
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Raw Material analysis of Escitalopram Oxalate   
 The raw material analysis of the Escitalopram oxalate was carried out the 
results were as follows.  
Table 8.1 Flow properties of Escitalopram oxalate API 
S.NO TEST RESULT 
1 Bulk density(g/ml) 0.200gm/ml 
2 Tap density(g/ml) 0.384 
3 Compressibility Index 48% 
4 Hausner Ratio 0.1923 
5 Angle of Repose 44.645 
 
INFERENCE:- 
From the above results flow property of the drug shows very poor 
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Table 8.2 Raw material analysis of the Escitalopram oxalate drug 
TEST SPECIFICATION RESULT 
Description A white to half white crystalline powder 
A white crystalline 
powder 
Melting point  
(0 C) 
Between 148-156.0 152.1to 153.9 
Water content by 
Kf (%w/w) NMT1.5 0.7 
Solubility  
Soluble in Dimethyl formide, in 
Dimethyl Sulfoxide, Sparingly soluble in 
methanol& slightly soluble in 
Dichloromethane  
Compiles  
Loss on drying 
(%) NMT 1.00%w/w 0.30% w/w 
Particle size (µ) NMT 30µ 11.1µ 
Assay (%) NLT 98.0%& NMT 102.0% 99.7% 
Residue on 
ignition (%w/w) NMT0.20% w/w 0.06% 
In House Specifications 
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Table 8.3 Drug Excipient Compatibility Studies 
NC-No change observed  
 
S.no Ingredient Ratio Description 
Initial Final 
40C±2C/75%±5 
I 
week 
II 
week 
III 
week 
IV 
week 
1 Escitalopram oxalate  White to half white 
crystalline powder 
NC NC NC NC 
2 Escitalopram oxalate 
+ LHPC-21 
1:1 White to half white 
crystalline powder 
NC NC NC NC 
3 Escitalopram oxalate 
+ Crospovidone CL-F 
1:1 White to half white 
crystalline powder 
NC NC NC NC 
4 Escitalopram oxalate 
+ Kyron T-314 
1:1 White to half white 
crystalline powder 
NC NC NC NC 
5 Escitalopram oxalate 
+ Aspartame  
1:0.05 White to half white 
crystalline powder 
NC NC NC NC 
6 Escitalopram oxalate 
+ Powdarome 
peppermint 
1:0.05 White to half white 
crystalline powder 
NC NC NC NC 
7 Escitalopram oxalate 
+ Powdarome orange 
1:0.05 White to half white 
crystalline powder 
NC NC NC NC 
8 Escitalopram oxalate 
+ Lake Sunset Yellow 
1:0.05 Slight orange  
crystalline powder 
NC NC NC NC 
9 Escitalopram oxalate 
+ Aerosil 
1:0.25 White to half white 
crystalline powder 
NC NC NC NC 
10 Escitalopram oxalate 
+ MCC pH 112 
1:10 White amorphous 
powder  
NC NC NC NC 
11 Escitalopram oxalate 
+ Mannitol  
1:10 White coloured 
amorphous powder 
NC NC NC NC 
12 Escitalopram oxalate 
+ Talc 
1:0.05 White to half white 
crystalline powder 
NC NC NC NC 
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INFERENCE:  
 From the above physical observation that all the excipients shows a good 
compatability with the drug no interactions or color changes observed. 
Table 8.4 Standard calibration curve of the Escitalopram oxalate 
Concentration(µg/ml) Absorbance at 239nm 
0 0 
2 0.0813 
4 0.1586 
6 0.2349 
8 0.3087 
10 0.3824 
Slope(m) 0.381 
Intercept 0.003 
Correlation 0.999 
 
 
 
 
 
 
Figure-8.2 Standard calibration curve of the Escitalopram oxalate 
 
Results and Discussion 
 
93 
 
Table 8.5 Results of Pre Compression Parameters 
BATCH NOS F1 F2 F3 F4 F5 F6 F7 F8 F9 
Angle of repose  48.32 37.45 34.76 32.98 40.5 38.04 32.56 29.65 28.98 
Bulk density  0.25 0.605 0.631 0.586 0.387 0.59 0.384 0.486 0.463 
Tap density  0.384 0.741 0.728 0.681 0.54 0.74 0.45 0.532 0.509 
Compressibility 
index 34.89 18.35 13.32 13.95 28.33 20.27 14.66 8.64 9.03 
Hausner ration 1.53 1.22 1.15 1.16 1.39 1.254 1.17 1.09 1.09 
 
 
              
 
 
 
 
Figure –8.3 Comparison of Angle of Repose of All Formulations 
INFERENCE:  
 Preformulation studies shows that Escitalopram Oxalate API dose not 
shows good flow property so it should be improved by the addition of the From this 
graph the initial batch F1 shows poor flow property where the filler used was MCC 
it was improved by the addition of Mannitol in F2,F3,F4 in increasing 
concentrations shows good flow properties . again the flow property was decresad 
by addition of Prosolv ODT at last in the final formula only the Mannitol filler 
shows the Excellent flow property in F8&F9. 
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Table 8.6 Results of Post Compresional Parameters 
Physical Appearance: - slight orange coloured tablets with break line  
Formulation 
Code 
Average 
weight 
(mg) 
±7.5% 
Thickness 
(mm) 
±5% 
Hardness 
(kp) 
Percentage Friability 
(%) 
0.1-0.9% 
In vitro 
Disintegration 
Time (sec) 
In vitro 
dispersion 
time(sec) 
Wetting 
time (sec) 
Assay 
F1 201 3.55 2.5 0.31 180 >7min 240 99.87% 
F2 199.6 3.54 2.3 0.20 68 132 118 97.91% 
F3 202.5 3.71 2.0 0.22 55 110 97 100% 
F4 200 3.89 2.2 0.10 49 65 45 101% 
F5 198.5 3.45 2.1 0.60 54 165 120 99.56% 
F6 202.1 3.56 2.7 0.34 32 121 104 97% 
F7 200 3.67 2.5 0.11 21 45 48 100% 
F8 200 3.71 3.4 0.09 14 34 24 101.05% 
F9 200 3.70 3.5 0.09 16 31 28 101.43% 
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Figure-8.4 Comparison of hardness of different formulations 
 
 
 
 
 
 
Figure-8.5 Comparison of percentage weight loss of different formulations 
INFERENCE:  
 From the figure12 &13 initially the hardness was low and the friability was more it 
was observed to improve by replacing the MCC by Mannitol increasing concentration of 
Mannitol results in the optiminsed hardness (3.5±0.5) and low friability (0.09%) in the final 
formulas F7,F8,F9. 
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Figure-8.6 Comparison of in vitro disintegration time 
INFERENCE:  
 Initially the tablet took more than 5 minutes to disintegrate. Since mannitol has  
multiple properties such as diluent, sweetenting agent and  as well as disintegrant , the 
concentration of mannitol was increased to make the tablet disintegrate at a faster rate. 
Optimization of disintegration time was made by studying  the inclusion of  super 
disintegrants such as LHPC-21, kyron T-314 and Crospovidone CL-F. Addition of cros 
povidone showed positive results in disintegration time of the tablets. Optimized 
disintegration time was obtained by increasing the % of super disintegrates. The above figure 
shows the disintegration time of various formulations. From the figure it could be inferred 
that formulation F9 got an optimized disintegration time of 16 ±3sec. 
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Figure-8.7 
INFERENCE:  
 ‘Wetting time’ is an important parameter to be considered while preparing an oral 
disintegrating tablet. Wetting time is carried out to determine the absorption capacity of the 
tablet which effects its disintegration. Initially the wetting time was around 4 minutes. 
Addition of the Mannitol with micro crystalline cellulose increased compactability and 
hardness of the tablet and results in decreased its wetting time. Wetting time was further more   
decreased by enhancing the disintegrating capacity of the tablet by inclusion of super 
disintegrates and increasing the concentration of the filler (Mannitol) in the final trials. The 
above figure shows the wetting time of various formulations of Escitalopram oxalate orally 
disintegrating tablets. From the figure it could be inferred that the wetting time was optimized 
and brought to 28 Seconds at F9. 
Invitro dispersion time  
 Initially the in vitro dispersion time was observed to be more than 5 mins it was 
gradually reduced by increasing the concentration of the super disintegrants and by increasing 
the concentration of the Mannitol as filler the above figure shows the in vitro dispersion time 
of various formulations of escitalopram oxalate orally disintegrating tablets. From the figure 
it could be observed that the wetting time was optimized and bought to 31seconds for F9. 
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TABLE 8.7 Dissolution study of Escitalopram Oxalate Oral Disintegrating Tablets 
Cumulative percentage of drug release (%) 
Time 
(min) 
F 1 F 2 F 3 F4 F5 F6 F7 F 8 F9 
0 0 0 0 0 0 0 0 0 0 
5 92.99 98.66 99.44 102.59 101.28 102.48 103.14 103.04 103.13 
10 96.3 98.74 100.71 102.37 102.46 102.66 103.65 103.54 103.65 
15 96.49 100.77 101.72 102.33 103.59 103.2 103.51 103.29 103.71 
20 98.83 102.14 102.27 101.47 101.02 101.22 102.75 101.79 103.75 
30 101.79 102.04 102.25 101.26 101.87 101.4 102.84 101.85 102.84 
 
 
 
 
 
 
 
Figure-8.8 Comparative dissolution profile of Different Formulations (F1, F2, F3, F4) 
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Figure-8.9 Comparative dissolution profile of Different Formulations (F5, F6, F7, F8) 
 
 
 
 
 
 
 
 
Figure-8.10 Dissolution profile of F9 Formulation
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RESULTS OF STABILITY DATA 
Table 8.8 Stability study data 
PARAMETERS 
TESTED 
STORAGE CONDITIONS 
INITIAL 
400C±20C / 75% 
±5% RH 
1st 
month 
2nd 
month 
Description Light orange coloured round tablet with break line 
No 
change 
No 
change 
Average weight 
(mg) 200 201 201 
Thickness 
(mm)  
3.71 3.71 3.73 
Hardness (kp) 3.4 3.4 3.3 
% Friability 0.09 0.12 0.17 
Disintegration 
time (sec) 14 18 20 
In  vitro 
dispersion time 34 39 51 
Water content 
(%) 2.41 2.33 2.45 
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Table 8.9 Dissolution data of stability study sample( percentage of drug release) 
Time 
Interval 
(min) 
Initial 
400C±20C / 75% ±5% RH 
Ist month 
 
2nd month 
0 0 0 0 
5 101.71 101.52 101.28 
10 103.52 102.60 102.46 
15 103.2 103.19 103.00 
20 101.77 101.76 101.02 
30 101.83 101.82 101.07 
 
 
 
 
 
 
 
Figure-8.11 
                                  Table 8.10 Assay of stability samples 
Storage conditions Escitalopram oxalate 
Initial 100.45% 
40
0 C
±2
0
C
 /
 7
5%
 
±
5%
 R
H
 1st month 99.87% 
2nd month 100.23% 
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DISCUSSION 
Formulation F1 
 F1 was carried Microcrystalline cellulose (Cyclocel pH112) as diluent, 
Crosspovidone XL (2.5%) & L-HPC (2.5%) as superdisintegrant. Aerosil is used as a 
glident the disintegration time was more than 3mins and in-vitro dispersion time was 
more than 7mins. 
Improvisation of trial  
 Addition of the another super disintegrate Kyron T314 (5%) 
Formulation F2 
 During the F2 batch trails were performed for optimizing the 
concentrations of the sweeteners and flavouring agents four different trials A, B, C 
and D. It was observed that Trial D showed good mouth feel. Hence the tablets were 
compressed with the formula for Trial D. 
 F2 was carried Microcrystalline cellulose (Cyclocel pH112) as diluent, 
Crosspovidone XL (2.5%) & L-HPC(2.5%) & KyronT314(5%)  as superdisintegrant. 
Hence e disintegration time was reduced to 68 seconds but fails in the in-vitro 
dispersion time and wetting time. 
Improvisation of trial  
 Increasing the concentration of the superdisintegrants 
 Addition of spray dried mannitol as a diluent 
 For the improvement of the wetting time and in-vitro dispersion time 
Formulation (F3) 
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 F3 Formulation was carried out by increasing the concentrations of the 
super disintegrate Crosspovidone (5%), kyron (7.5%), L-Hpc (5%).and using the 
combination of the diluent Micro crystalline cellulose and mannitol. Hence the 
disintegration time was reduced but still the wetting time was not yet improved 
Improvisation of trial  
 Further increasing in the concentration of the spray dried mannitol 
30% as diluent 
Formulation (F4) 
 Formulation F4 was carried out with increased concentration of the 
mannitol (30%) as diluent results in good improvement in the disintegration 
time(65sec) and wetting time(45 sec). 
Improvisation of trial  
 Replacing the excipients with PROSOLV ODT which is a 
combination of the Microcrystalline Cellulose, Colloidal Silicon 
Dioxide, Mannitol, Fructose, and Crospovidone. 
Formulation (F5) 
 F5 was carried out by using the Prosolv ODT (60%) as  excipent specially 
designed for the orally disintegrating tablet here the disintegration time was increased 
and wetting time was also increased and the sticking problem was also observed 
during compression. 
Improvisation of trial  
 Decreasing the concentration of the Prosolv ODT and addition of 
the spray dried mannitol. 
 Additions of crospovidone as super disintegrate.  
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Formulation (F6) 
 F6 formulation was carried out with addition of spray dried mannitol (25%) 
and Aerosil (2.5%) and crospovidone (5%) hence observed improvisation in the 
wetting time and disintegration time 
Improvisation of trial  
 Increase in concentration of Spray dried mannitol and Aerosil 
Formulation (F7) 
 F6 formulation was carried out with addition of spray dried mannitol (40%) 
and aerosil (7.5%) as a suspending agent  hence observed improvisation in the wetting 
time (48sec) and disintegration time (21) hence concluded that Prosolv ODT does not 
show the impact on this formulation. 
Improvisation of trial  
 Replacing the Prosolv ODT with Spray dried mannitol and Aerosil 
Formulation (F8)  
 F8 formulation was carried out with mannitol as a filler and crospovidone, 
KyronT314 & L-Hpc 21 as a super disintegrates results in good wetting time 
(24sec)and disintegration time (14sec). 
Formulation (F9)  
Reproducibility batch of F8 
All the pre compression and the post compression parameters showed good results 
Summary 
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9. SUMMARY 
 
 A recent advance in Novel Drug Delivery System aims to enhance safety 
to enhance safety and efficacy of drug molecule by formulating a convenient dosage 
form for administration and to achieve better patient compliance. One such approach 
is Orally Disintegrating Tablet. 
 The present study was to formulate and standardize of an Anti depressant 
drug Escitalopram Oxalate. Escitalopram Oxalate orally disintegrating tablets 
formulated in the present study are beneficial to the pediatrics and elderly patients. It 
is also beneficial to the person having Dysphagia and mentally ill. 
Preformulation studies were carried out during the early stages of this work. It 
was found that Escitalopram oxalate is having maximum absorbance at wavelength 
239 nm. The drug-polymer compatibility study was carried out to determine the 
interactions between the drug and the polymers used in the study. 
 The orally disintegrating tablets were formulated using the above 
mentioned difrent super disintegrants by direct compression technique. 
Crospovidone, LHPC-21 and  Kyron T-314 were used as super disintegrants . 
 Prepared tablets were evaluated for Pre-Compression Parameters and Post 
compression Parameters. 
 Flow properties –Angle of repose, Bulk density, Tap Density and also 
%compressability was determined to all formulations which showed good flow 
property. 
 Formulation F1 was carried Microcrystalline cellulose (Cyclocel pH112) 
as diluents, Crosspovidone XL (2.5%) & L-HPC (2.5%) as Superdisintegrants. 
Aerosil is used as a glident. here shows the DT more than 3mins to improve the 
disintegration time the addition of the super disintegrants  KYRONT-314 ,the 
Summary 
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disintegration time was improved but still the wetting time and the invitro dispersion 
time were not improved for this reason the Spray dried Mannitol was used as 
diluents and concentration of super disintegrants was increased in F3.As the 
increasing the concentration of the diluents Mannitol results in the  good wetting 
time and invitro dispersion. 
 F5,F6,F7 were prepared by using Prosolv ODT which does not give good 
results so the increasing concentration of Mannitol and the cross provide were used 
again gives the best result. F8 were carried out with Mannitol as filler and 
Crospovidone, Kyron T-314 &L-HPC 21 as super disintegrates results in good 
wetting time 24 sec and disintegration time 14 seconds. 
 The final trials F8, F9 were optimized with various tablet parameters like 
Thickness (3-4)mm; Hardness (3-4) kp; Percentage Friability (<1%) and 
Disintegration time (14±3 seconds), which were within the specified limits. The 
Dissolution and Assay results of F8 and F9 were good 
 Moisture uptake studies for the final batch were performed at 29, 43% RH 
The reproducibility batch F9 was loaded for long term and accelerated stability 
studies at 40±2C/75±5% RH. The results of stability data for 1st and 2nd month 
(40±2C/75±5% RH) were found to be good. Not much variation or changes found 
during study period. 
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10. CONCLUSION 
 
 Escitalopram Oxalate used as Antidepressant. They are formulated as oral 
disintegrating tablets which show better patient acceptability and compliance with 
improved efficacy when compared with conventional dosage forms. 
 Direct compression was the preferred technology for the preparation of 
oral disintegrating tablets of Escitalopram Oxalate. 
 Based on the preliminary studies various formulation trials (F1-F9) were 
carried out with different concentrations of Superdisintegrants, filers and lubricants. 
From the various formulations it was concluded that the formulation F9, the 
reproducibility batch of F8 was finalized as the optimized formula. 
 Formulation F9 showed satisfactory results with various physicochemical 
evaluation parameters like Hardness, Percentage weight loss, Disintegration time, 
Dissolution profile, Assay and Moisture content. When subjected to accelerated 
stability studies the tablets were found to be stable. 
 
